AUTHORIZES BONDS TO CONTINUE FUNDING STEM CELL AND OTHER MEDICAL RESEARCH. INITIATIVE STATUTE. by unknown
University of California, Hastings College of the Law 
UC Hastings Scholarship Repository 
Initiatives California Ballot Propositions and Initiatives 
12-17-2019 
AUTHORIZES BONDS TO CONTINUE FUNDING STEM CELL AND 
OTHER MEDICAL RESEARCH. INITIATIVE STATUTE. 
Follow this and additional works at: https://repository.uchastings.edu/ca_ballot_inits 
 December 17, 2019 
Initiative 19-0022 (Amdt. #1) 
 
 
The Attorney General of California has prepared the following title and summary of the chief 
purpose and points of the proposed measure: 
AUTHORIZES BONDS TO CONTINUE FUNDING STEM CELL AND OTHER 
MEDICAL RESEARCH.  INITIATIVE STATUTE.  Authorizes $5.5 billion in state general 
obligation bonds to fund grants from the California Institute of Regenerative Medicine to 
educational, non-profit, and private entities for:  (1) stem cell and other medical research, therapy 
development, and therapy delivery; (2) medical training; and (3) construction of research 
facilities.  Dedicates $1.5 billion to fund research and therapy for Alzheimer’s, Parkinson’s, 
stroke, epilepsy, and other brain and central nervous system diseases and conditions.  Limits 
bond issuance to $540 million annually.  Appropriates money from General Fund to repay bond 
debt, but postpones repayment for first five years.  Summary of estimate by Legislative Analyst 
and Director of Finance of fiscal impact on state and local governments:  State costs of $7.8 
billion to pay off principal ($5.5 billion) and interest ($2.3 billion) on the bonds.  Associated 
average annual debt payments of about $310 million for 25 years.  The costs could be 
higher or lower than these estimates depending on factors such as the interest rate and the 
period of time over which the bonds are repaid.  The state General Fund would pay most of 
the costs, with a relatively small amount of interest repaid by bond proceeds.  (19-0022A1.) 
 
 i 9  0 0 2  2  Amdt.  # l
November  4, 2019 
VIA  MESSENGER 
RECEIVED 
Office  of  the  Attorney  General 
1300  'T'  Street,  1  7th  Floor NOV 1 8  2019 
Sacramento,  CA  95814 
INITIATIVE COORDINATOR 
Attention:  Initiati-ve  Coordinator ATTORNEY GENERAL'S OFFICE 
Re:  Submission  of  Amertdments  to  The  California  Stem  Cell Research, 
TreatmeMs,  and Cures  Initiative  of  2020,  No.  19-0022,  and Request  to 
Prepare  Circulating  Title  and  Summary  (Amendment) 
Dear  Initiative  Coordinator 
On  October  10,  2019,  I  submitted  a  proposed  statewide  initiative  titled  "The 
California  Stem  Cell  Research,  Treatments,  and Cures  Initiative  of  2020"  ("Initiative")  and 
submitted  a  request  that  the  Attorney  General  prepare  a  circulating  title  and sumi'nary  pursuant  to 
section  10(d)  of  Article  II  of  the  California  Constitution. 
Pursuant  to Elections  Code  section  9002(b),  I hereby  submit  timely  amendments  to 
the  text  of  the  Initiative.  As  the  proponent  of  the  Initiative,  I approve  the submission  of  the  amended 
text  to the  Initiative  and I declare  that  the  amendment  is reasonably  germane  to the  theme,  purpose, 
and subject  of  the  Initiative.  I respectfully  request  that  the  Attorney  General  prepare  a  circulating 
title  and summary  using  the  amended  Initiative  (Amendment). 
Sincere 
Klein 
Enclosures 
(00393939) 
        
  
  
                
   
    
             
                
           
             
            
              
              
            
              
             
               
                
                 
            
              
            
          
            
   
           
              
               
          
             
                  
                  
               
             
              
Amended 11.18.19 
THE CALIFORNIA STEM CELL RESEARCH, TREATMENTS, AND CURES 
INITIATIVE OF 2020 
SEC. 1. Title. 
This measure shall be known and may be cited as "The California Stem Cell Research, Treatments, and 
Cures Initiative of 2020." 
SEC. 2. Findings and Declarations. 
The People of the State of California hereby find and declare all the following: 
A. In 2004, California voters rejected efforts by the federal government to limit stem cell research by 
establishing California's own stem cell research and therapy development funding institute, catapulting 
California into a worldwide leadership position in the cutting-edge field of stem cell research. 
B. Since then, the California Institute for Regenerative Medicine (California's stem cell research 
institutel which was established by California voters, has funded more than 1,000 research projects at 
70 institutions and businesses across the state, which have led to more than 2,500 peer-reviewed 
medical research discoveries, including discoveries that have contributed to more than 70 human 
clinical trials aimed at finding treatments and cures for chronic injuries and diseases. Many other 
discoveries are in the translational pipeline awaiting additional funds to move them towards clinical 
trials. To date, approximately 2,000 patients have been or are expected to be treated in institute-
funded clinical trials or at the institute's centers of excellence, and more than 4,000 patients have been 
or are expected to be enrolled in human clinical trials in which the California stem cell research institute 
has funded research or therapy development or at the institute's centers of excellence. 
C. Researchers funded by California's stem cell research institute are working to develop therapies and 
cures for devastating diseases and injuries, including without limitation, cancer, diabetes, heart disease, 
lower respiratory diseases, kidney disease, Alzheimer's, Parkinson's, spinal cord injuries, blindness, 
amyotrophic lateral sclerosis (ALS), HIV/AIDS, multiple sclerosis, and mental health disorders, such as 
schizophrenia, depression, and autism. 
D. Institute-funded researchers are making significant progress in developing therapies for many 
devastating diseases, ranging from cancer treatments to helping to find a cure for "bubble baby" 
disease, which has already saved the lives of many children, but many of these projects require 
additional funds to move from the research stage to the clinic. 
E. Treatments developed with support from California's stem cell research institute are changing lives. 
Thanks to this research, a high school student who was paralyzed in a diving accident was able to regain 
function in his upper body and go on to college; a mother who went blind from a genetic disease 
recovered her sight; and a cure has been found for a disease that causes fetal death. 
F. Through 2018, institute-funded research projects are estimated to have generated more than S3 
billion in matching funds, created more than 55,000 (FTE) jobs in California, resulted in approximately 
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Amended 11.18.19 
5641 million in state and local tax revenues, and generated an increase of !>10.7 billion in California's 
economic activity. California's stem cell research institute has drawn hundreds of out-of-state 
researchers and many companies to California, making California a worldwide leader in the field. The 
more than 53 billion dollars in matching funds generated by these projects validate the value of the 
voters' decision to invest in research and therapies to treat and cure chronic disease and injury. 
G. Although California"s stem cell research funding institute has made great gains, much work remains 
to be done. With new federal restrictions on important research, an anti-science agenda on the rise, 
and threats to reduce federal research and development funding, California once again must take the 
lead to ensure that this promising area of research continues and to advance projects from the research 
stage to the clinic. 
H. Without additional funding, many of these promising research and development projects will be 
forced to stop work on potentially life-changing medical therapies. California's stem cell research 
institute needs additional funding to help bring promising discoveries through the development process, 
including clinical trials, with the goal of making treatments available to California patients with chronic 
diseases and injuries. 
SEC. 3. Purpose and Intent. 
In enacting this Initiative, it is the purpose and intent of the people of the State of California to continue 
to support stem cell research to mitigate and/or cure chronic disease and injury and thereby reduce or 
mitigate human suffering and the cost of care and improve the health and productivity of Californians 
by: 
A. Providing SS.5 billion in bond funding to allow California's stem cell research institute to continue 
funding stem cell and other vital research to develop treatments and cures for serious diseases and 
conditions like diabetes, cancer, HIV/AIDs, heart disease, paralysis, blindness, kidney disease, respiratory 
illnesses, and many more. 
B. Dedicating S1.5 billion (one billion, five hundred million dollars) for the support of research and the 
development of treatments for diseases and conditions of the brain and central nervous system, such as 
Alzheimer"s disease, Parkinson"s disease, stroke, dementia, epilepsy, depression, brain cancer, 
schizophrenia, autism, and other diseases and conditions of the brain. 
C. Promoting the accessibility and affordability of treatments and cures by ensuring that more 
Californians have the opportunity to participate in clinical trials for promising new treatments for 
chronic disease and injury, expanding the number and geographic reach of clinics where specialized 
treatments and cures can be provided, including centers of excellence like Alpha Stem Cell Clinics and 
Community Care Centers of Excellence, which support clinical trials and will serve as the foundation for 
the delivery of future treatments, and by helping California patients obtain treatments and cures that 
arise from institute-funded research and development. 
D. Requiring strict accountability and transparency, including rigorous conflict of interest rules that are 
updated every four years, a limit on the number of employees the institute may hire, and a cap on 
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Amended 11.18.19 
administrative funding for the institute to ensure that at least 92.5% of the bond proceeds are spent on 
research and the development and delivery of treatments and cures. 
E. Creating the workforce jobs necessary to ensure that promising research developments are advanced 
to the clinic and that resulting treatments are made available to California patients. 
F. Reinforcing California's position as a world leader in the development of stem cell treatments and 
cures for patients. 
G. Promoting private investment in institute-funded projects to leverage institute funding so that this 
critical research can advance new treatments faster towards the goal of making them available to 
California patients. 
H. Protecting the General Fund by postponing general fund payments on the bonds for the first five 
years, restricting the issuance of bonds in any one year to no more than one half of one percent of the 
total amount of the state's outstanding and authorized General Obligation bonds, in the aggregate total, 
as of January 1, 2020, requiring that bonds be sold over a period of no less than ten years, and spreading 
the cost of the bonds over a period of up to 40 years, so that the repayment is aligned with the period of 
time over which California patients are expected to benefit from institute-funded research. 
SEC. 4. Section 125290.72 is added to the Health and Safety Code to read as follows: 
125290. 72. Expand Alpha Stem Cell Clinic Proqram and Establish Community Care Centers of 
Excellence Proqram. 
(a) The institute shall expand the Alpha Stem Cell Clinic Proqram and establish the Community Care 
Centers of Excellence Proqram to fund the establishment of centers of excellence at which clinical trials 
are conducted and treatments and cures made available for all patients. The qoal of the Community 
Cr:ireCenters of Excellence Proqram is to expand the capacity of the Alpha Stem Cell Clinic Proqram to 
promote access to human clinical trials and the accessibility of treatments and cures arisinq from 
institute-funded research for patients in California by establishinq qeoqrr:iphically diverse centers of 
excellence to conduct clinical trir:ils and to seek to make the resultinq treatments and cures broadly 
available to California patients. 
(b) The institute shall prioritize the fundinq of applications for Community Care Centers of Excellence that 
enhance the qeoqraphic distribution of Community Care Centers of Excellence across the state, 
considerinq the location of the Alpha Stem Cell Clinics, to promote patient access. The institute shall 
prioritize applications for Alpha Stem Cell Clinics and Community Care Centers of Excellence that offer 
matchinq funds and/or verified in-kind support, consistent with the hiqhest medical standards, as 
established by the Governinq Board of the institute. 
(c) Applications for Alpha Stem Cell Clinic and Community Care Centers of Excellence qrants shall be 
required to include a plan for enhancinq access to clinical trials for California patients and makinq 
treatments and cures that arise from institute-funded research more widely available to California 
patients, includinq addressinq how the applicant will support the ancillary hospital and accesscosts of 
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Amended 11.18.19 
patients participatinq in clinical trials to enhance access to trials for California patients, reqardless of 
their economic means and qeoqraphical location. 
(d) Alpha Stem Cell Clinic and Community Care Centers of Excellence awards shall be made pursuant to 
the procedures set forth in Article /, Chapter 3, Division 106, Part 5 of the Health and Safety Code. 
SEC. 5. Section 125290.73 is added to the Health and Safety Code to read as follows: 
125290.73. Scientific and Medical Traininq and Fellowship Proqrams. 
(a) The institute shall establish traininq and fellowship proqrams. The qoal of the traininq and fellowship 
proqrams shall be to: (1) ensure that California has the workforce necessary to move new discoveries 
from the research staqe to the clinic; (2) accelerate the accessibility of treatments and cures, and to 
make treatments and cures arisinq from institute-funded research available to California patients; (3) 
prepare California underqraduates and masteYs students for careers in stem cell research and other vital 
research opportunities and in the development and delivery of treatments and cures; and (4) to support 
qraduate students, post-doctoral students, and medical students, includinq but not limited to interns, 
residents, and qraduate fellows who work in the fields of stem cell and other vital research opportunities 
and in the development and delivery of treatments and cures, with fellowships. 
(1) (A) The proqram shall provide awards to California community colleqes and California State 
University campuses to establish traininq proqrams to prepare underqraduates and provide 
fellowships for master's qraduate students for advanced deqrees and technical careers in stem 
cell research and other vital research opportunities and the development and delivery of 
treatments and cures, includinq hands-on traininq and education in stem cell research and other 
vital research opportunities and in the development and delivery of treatments and cures. 
Direct patient enqaqement and outreach activities that enqaqe California's diverse communities 
to ensure that all communities are avmre of, and have access to, institute-funded treatments and 
cures shall be a priority outcome of this proqram. The institute shall prioritize the fundinq of 
applications from institutions that enhance the qeoqraphic distribution of traininq across the 
state and socio-economic diversity and applications that offer matchinq funds or verified in-kind 
support. 
(B) The institute may establish co-investment, sponsored apprenticeships as part of the traininq 
proqram in order to leveraqe the institute's fundinq and create employment opportunities for 
students in technical positions that advance the fields of stem cell and other vital reser:irch 
opportunities and the development and delivery of treatments and cures. 
(2) (A) The fellowship proqram shall provide awards to academic and nonprofit research institutions in 
California to administer fellowship awards to qraduate and post-doctoral students and medical school 
students, includinq but not limited to interns, residents, and qraduate fellows, enqaqed in stem cell 
research and other vital research opportunities and the development and delivery of treatments 
and cures. Fellowship awards may be free-standinq or supplemental of other sources of 
fundinq. 
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Amended 11.18.19 
(B) The institute may establish a proqram to empower fellows to work in Alpha Stem Cell Clinics 
and Community Care Centers of Excellence as part of their participation in the fellowship 
proqram. 
(b) Traininq and fellowship proqram awards shall be made pursuant to the procedures set forth 
in Article /, Chapter 3, Division 106, Part 5 of the Health and Safety Code. 
SEC. 6. Section 125290.74 is added to the Health and Safety Code to read as follows: 
125290. 74. Shared Research Laboratory Proqram. 
(a) The institute shall re-establish a Shared Research Labomtory Proqram to provide fundirHl to academic 
and nonprofit research institutions in California for specialized instrumentation, a supply of cell lines, 
culture materials, and instruction and traininq in research methods and techniques. Awardees of Shared 
Research Laboratory qrants shall be required to offer use of the research laboratory to investiqators 
conductinq research at the awardee institution and to provide a reasonable access plan for neiqhborinq 
research institutions, and to offer instruction and traininq opportunities to students and investiqators at 
the awardee institution and to provide a reasonable access plan for neiqhborinq research institutions. 
(b) The institute shall prioritize the fundinq of applications that enhance the qeoqraphic distribution of 
Shared Research Laboratories across the state and applications that offer matchinq funds or verified in-
kind support. 
(c) Shared Research Laboratory Proqram awards shall be made pursuant to the procedures set forth 
in Article /, Chapter 3, Division 106, Part 5 of the Health and Safety Code. 
SEC, 7. Section 125290.75 is added to the Health and Safety Code to read as follows: 
125290.75. Treatments and Cures Accessibility andAffordability Workinq Group. 
(a) Membership 
The Treatments and Cures Accessibility and Affordability Workinq Group shall have 1 7 members 
nominated by the Chair or Vice Chair and approved by the Board as follows: 
(1) Five members of the ICOC (the "Governinq Board"), with at least two of those members drawn from 
the appointments made pursuant to paraqraphs (3), (4), (5) or (6) of subdivision (a) of Section 
125290.20. 
(2) An individual who has private sector experience in innovative therapy medical coveraqe terms, 
qualifications, and the process for reimbursement, includinq, if possible, experience with coveraqe 
neqotiations with private insurers, health manaqement orqanizations, or corporate self-insurance health 
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Amended 11.18.19 
(3) An expert or a hiqhly knowledqeable individual with experience in federal therapy coveraqe, 
qualifications, and process for reimbursement, includinq, if possible, experience with the Centers for 
Medicare and Medicaid Services. 
(4) An expert or a hiqhly knowledqeable individual with experience in California's public insurance 
proqram (Covered California), coveraqe, qualifications, and the process for reimbursement of innovative 
therapies. 
(5) Two representatives from hospitals in California that are participatinq in stem cell clinical trir:ils or 
that are treatinq patients with Federal Druq Administration-approved stem cell or qenetic therapies. 
(6) A representative from o philanthropic orqanization who has experience assistinq patients with clinical 
trial access and affordability, or with access to, and the affordability of, innovative therapies. 
(7) Two representatives from patient advocacy orqanizations who have technical expertise or experience 
in coveraqe, qualifications, and the process for reimbursement of innovative therapies. 
(8) A health care economist, with experience in advisinq or neqotiatinq with private insurers, qovernment 
insurers, or corporate self-insurance proqrams on coveraqe for innovr:itive therapies or humr:in trials, 
includinq experience in assistinq hospitals and clinics in coverinq financial qaps in coveraqe of the direct 
and indirect costs of innovr:itive therapies. 
(9) A patient naviqator with traininq and experience helpinq patients obtain financial support from 
private insurers, public support, or nonprofit support, and helpinq patients obtain socir:il service support 
to facilitate their participation in Federal Druq Administration-approved human trials or their 
qualification for access and financial assistance for innovative therapies. 
(IO) The chairperson and vice chairperson of the Governinq Board. 
(b) Functions 
The Treatments and Cures Accessibility and Affordability Workinq Group shall have the followinq 
functions: 
(1) To examine, develop, and assist with the implementation of financial models to enhance the 
accessibility and affordability of treatments and cures arisinq from institute-funded research for 
Californir:ins, and to enhance access to clinical trials, includinq reimbursement alternatives for patient-
qualified costs to help achieve the objective that reimbursement covers patient expenses, includinq but 
not limited to, medical expenses, lodqinq, meals, and travel for research participants and their 
careqive rs. 
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Amended 11.18.19 
(2) To recommend to the Governinq Board policies and proqrams to help Californians obtain access to 
human clinical trials and to make treatments and cures arisinq from institute-funded research available 
to California patients throuqhout California. 
(3) To recommend to the Governinq Board policies and proqrams to help Californians afford to 
participate in human clinical trials and to make treatments and cures arisinq from institute-funded 
research r:iffordable to California patients, reqardless of their financial means. 
(4) To work with the Alpha Stem Cell Clinics and Community Care Centers of Excellence and other 
California healthcare institutions, and healthcare payors, includinq private insurers, qovernment 
proqrams, and foundations, to develop model proqrams and coveraqe models to promote the access and 
affordability of treatments and cures arisinq from institute-funded research for California patients, 
reqardless of their financial means, or the disease, iniury, or health condition from which they suffer. 
(5) To advise the Governinq Board reqardinq the coveraqe criteria and the process for reimbursement of 
innovative therapies and cures arisinq from institute-funded research and made available to patients 
throuqh publicly or privately-funded proqrams in California with the qoal of expandinq access and 
affordability. 
SEC. 8. Section 125290.76 is added to the Health and Safety Code to read as follows: 
125290.76. Advisory Task Forces. 
(a) Membership 
The Chair and the President may appoint one or more advisory task forces to provide expert quidance to 
address specific obiectives in areas under the institute's iurisdiction, includinq scientific, policy, ethical, 
financial, and technical matters. The Chair and President shall each appoint r:inequal number of 
members with expertise in the area or areas for which advice is souqht, includinq at least one member 
who has a patient advocate perspective. 
(b) Functions 
The advisory task forces shall advise the Board throuqh the Chair and the President, reqardinq scientific, 
policy, financial, ethical, and technical matters under the institute's iurisdiction. 
(c) Operr:itions 
(1) The advisory task forces shall be advisory only and their operations shall be subiect to the 
requirements applicable to workinq qroups pursuant to Section 125290.50, provided that the task forces 
shall meet in public when they vote on policy recommendations. 
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Amended 11.18.19 
(2) Members of the advisory task forces shall be subiect to the conflict of interest requirements 
applicable to members of the workinq qroups, provided that the advisory task forces shall not review, 
comment upon, or have iurisdiction over any individual qrant or loan approval. 
SEC. 9. Section 125290.20 of the Health and Safety Code is hereby amended to read as follows: 
125290.20. ICOC Membership; Appointments; Terms of Office. 
(a) ICOC Membership 
The ICOC shall have 2-!;)35 members, appointed as follows: 
(1) The Chancellors of the University of California at San Francisco, Davis, San Diego, Los AngelesL 
Irvine, and Riverside shall each appoint an executive officer from his or her campus. In addition, the 
Chancellor of the University of California at San Francisco shall also appoint a faculty member, 
physician/scientist, researcher, or executive officer from the UCSFFresno/Clovis campus to promote 
qeoqraphic diversity and access. 
(2) The Governor, the Lieutenant Governor, the Treasurer and the Controller shall each appoint an 
executive officer from the following three categories: 
(A) A California university, excluding the seven campuses of the University of California described in 
paragraph (1), that has demonstrated success and leadership in stem cell research, other vital research 
opportunities, therapy development, or therapy delivery, and that has: 
(i) A nationally-ranked research hospital and medical school; this criteria will apply to only two of the 
four appointments. 
(ii) A recent proven history of administering scientific and/or medical research grants and contracts in an 
average annual range exceeding SIOO million. 
(iii) A ranking within the past five years in the top 10 United States universities with the highest number 
oflife-science patents or that has research or clinical faculty who are members of the National Academy 
of Sciences. 
(iv) For purposes of this cateqory, the Governor may appoint an executive officer from the California 
State University system who has an advanced deqree in bioloqical sciences. 
(B) A California non-profit academic and research institution that is not a part of the University of 
California, that has demonstrated success and leadership in stem cell research, other vital research 
opportunities, therapy development, or therapy delivery, and that has: 
(i) A nationally-ranked research hospital or that has research or clinical faculty who are members of the 
National Academy of Sciences. 
(ii) A proven history in the last five years of managing a research budget in the life sciences exceeding 
S20 million annually. 
(C) A California life-science commercial entity that is not actively engaged in researching or developing 
therapies or therapy delivery with pluripotent or progenitor stem cells or qenetic medical treatments, 
            
                
                
             
    
                
               
                
                
             
            
 
               
          
               
             
 
                
   
               
  
               
             
              
           
               
      
              
            
                
                
   
   
              
    
             
      
Amended 11.18.19 
that has a background in implementing l or developinq experimental medical therapies, 
includinq conductinq human clinical trials, and that has not been awarded, or applied for, funding by the 
Institute at the time of appointment. A board member of such entity who qenerally meets the same 
qualifications with a succcsr,ful history of developing innovative medical therapies may be appointed in 
lieu of an executive officer. 
(D) Only one member shall be appointed from a single university, institution, or entity for the purposes 
of paragraph (2). The executive officer of a California university, a nonprofit research institution or life 
science commercial entity who is appointed as a member, may from time to time delegate those duties 
to an executive officer of the entity or to the dean of the medical school, if applicable. 
(3) The Governor, the Lieutenant Governor, the Treasurer, and the Controller shall appoint members 
from among California representatives of California regional, state, or national disease advocacy groups, 
as follows: 
(A) The Governor shall appoint t-we three members, one from each of the following disease advocacy 
groups: spinal cord injury; Alzheimer's disease; and mental health conditions. 
(B) The Lieutenant Governor shall appoint three members, one from each of the following disease 
advocacy groups: type II diabetesy multiple sclerosis or amyotrophic lateral sclerosis; and mental 
health conditions. 
(C) The Treasurer shall appoint two members, one from each of the following disease groups: type I 
diabetes and heart disease. 
(D) The Controller shall appoint two members, one from each of the following disease groups: cancer 
and Parkinson"s disease. 
(4) The Speaker of the Assembly shall appoint a member from among California representatives of a 
California regional, state, or national mental health disease or mental health conditions advocacy group. 
(5) The President pro Tempore of the Senate shall appoint a member from among California 
representatives of a California regional, state, or national HIV/AIDS disease advocacy group. 
(6) The Treasurer and Controller shall each r:ippoint a nurse with experience in clinical trial manaqement 
and/or stem cell or qenetic therapy delivery. 
p 14 chairperson and vice chairperson who shall be elected by the ICOC members. Each 
constitutional officer shall nominate a candidate for chairperson and another candidate for vice 
chairperson. The chairperson and vice chairperson shall each be elected for a term of six years. The 
chairperson and vice chairperson of ICOC shall be full- or part-time employees of the institute and shall 
meet the following criteria: 
(A) Mandatory Chairperson Criteria 
(i) Documented history in successful stem cell research or other vital research opportunity in t 
development and/or therapy delivery advocacy. 
(ii) Experience with state and federal legislative processes that must include some experience with 
medical legislative approvals of standards and/or funding. 
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Amended 11.18.19 
(iii) Qualified for appointment pursuant to paragraph (31 (4), or (5) of subdivision (a). 
(iv) Cannot be concurrently employed by or on leave from any prospective grant or loan recipient 
institutions in California. 
(B) Additional Criteria for Consideration: 
(i) Experience with governmental agencies or institutions (either executive or board position). 
(ii) Experience with the process of establishing government standards and procedures. 
(iii) Legal experience with the legal review of proper governmental authority for the exercise of 
government agency or government institutional powers. 
(iv) Direct knowledge and experience in bond financing. 
The vice chairperson shall satisfy clauses (i), (iii), and (iv) of subparagraph (A). The vice chairperson shall 
be selected from among individuals who have attributes and experience complementary to those of the 
chairperson, preferably covering the criteria not represented by the chairperson's credentials and 
experience. 
(b) Appointment of ICOC Members 
(1) All appointments shall be made within 40 days of the effective date or this act. In the event that any 
of the appointments are not completed within the permitted timeframe, the ICOC shall proceed to 
operate with the appointments that are in place, provided that at least 60 percent of the appointments 
have been made. 
(2) Forty-five days after the effective date of this act, the Controller and the Treasurer, or if only one is 
available within 45 days, the other shall convene a meeting of the appointed members of the ICOC to 
elect a chairperson and vice chairperson from among the individuals nominated by the constitutional 
officers pursuant to paragraph (7) of subdivision (a). 
(c) ICOC Member Terms of Office 
(1) The members appointed pursuant to paragraphs (1), (3), (4i ai (5) of subdivision (a) shall 
serve eight-year terms, and all other members shall serve six-year terms. Members shall serve a 
maximum of two terms, unless earlier removed pursuant to paraqraph (5). 
(2) If a vacancy occurs within a term, the appointing authority shall appoint a replacement member 
within X 90 days to serve the remainder of the term. 
(3) When a term expires, the appointing authority shall appoint a member within 'W 90 days. ICOC 
members shall continue to serve until their replacements are appointed. 
(4) Notwithstandinq paraqraph (1), the appointinq authority may replace a member, other than the 
Chair or Vice Chair, who has served, as of the effective date of the Act addinq this paraqraph, at least 
half of the membeYs current term by appointinq a new member, who shall be eliqible to serve a full 
term. Such appointments shall be made within 90 days of the effective date of the Initiative addinq this 
paraqraph. 
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(5) The ICOCmay, by a vote of sixty percent (60%) of a quorum, recommend the removal of a member by 
the membeYs appointinq authority, or in the case of the chairperson and the vice chairperson, the 
nominatinq authority, or nominatinq authorities if more than one constitutional officer nominated the 
person.The appointinq authority, or nominatinq authority or authorities in the case of the chairperson 
and vice chairperson, shall have the authority to remove the member, or chairperson or vice chr:iirperson, 
respectively, upon receipt of the ICOC's recommendation. If more than one constitutional officer 
nominated the chairperson or vice chairperson, each of them must aqree in order to remove the 
chairperson or vice chairperson. 
SEC.10. Section 125290.30 of the Health and Safety Code is hereby amended to read as follows: 
125290.30. Public and Financial Accountability Standards. 
(a) Annual Public Report 
The institute shall issue an annual report to the public which sets forth its activities, grants awarded, 
grants in progress, research accomplishments, and future program directions. Each annual report shall 
include, but not be limited to, the following: the number and dollar amounts of research and facilities 
grants; the grantees for the prior year; the institute's administrative expenses; an assessment of the 
availability of funding for stem cell research from sources other than the institute; a summary of 
research findings, including promising new research areas; an assessment of the relationship between 
the institute's grants and the overall strategy of its research program; and a report of the institute's 
strategic research and financial plans. 
(b) Independent Financial Audit for Review by State Controller 
The institute shall annually commission an independent financial audit of its activities from a certified 
public accounting firm, which shall be provided to the Controller, who shall review the audit and 
annually issue a public report of that review. 
(c) A performance audit shall be commissioned by the institute every three years beginning with the 
audit for the 2010-11 fiscal year. The performance audit, which may be performed by the Bureau of 
State Audits, shall examine the functions, operations, management systems, and policies and 
procedures of the institute to assess whether the institute is achieving economy, efficiency, and 
effectiveness in the employment of available resources. The performance audit shall be conducted in 
accordance with government auditing standards, and shall include a review of whether the institute is 
complying with ICOC policies and procedures. The performance audit shall not be required to include a 
review of scientific performance. The first performance audit shall include, but not be limited to, all of 
the following: 
(1) Policies and procedures for the issuance of contracts and grants and a review of a representative 
sample of contracts, grants, and loans executed by the institute. 
(2) Policies and procedures relating to the protection or treatment ofintellectual property rights 
associated with research funded or commissioned by the institute. 
(d) All administrative costs of the audits required by subdivisions (b) and (c) shall be paid by the 
institute. 
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Amended 11.18.19 
(e) Citizen's Financial Accountability Oversight Committee 
There shall be a Citizen's Financial Accountability Oversight Committee chaired by the Controller. This 
committee shall review the annual financial audit, the Controller's report and evaluation of that audit, 
and the financial practices of the institute. The Controller, the Treasurer, the President pro Tempore of 
the Senate, the Speaker of the Assembly, and the Chairperson of the ICOC shall each appoint a public 
member of the committee. Committee members shall have medical or patient advocacy backgrounds 
and knowledge of relevant financial matters. The committee shall provide recommendations on the 
institute's financial practices and performance. The Controller shall provide staff support. The 
committee shall hold a public meeting, with appropriate notice, and with a formal public comment 
period. The committee shall evaluate public comments and include appropriate summaries in its annua 
report. The ICOC shall provide funds for all costs associated with the per diem expenses of the 
committee members and for publication ofthe annual report. 
(f) Public Meeting Laws 
(1) The ICOC shall hold at least twe public meetings per year, one of which will be designated as the 
institute's annual meeting. The ICOC may hold additional meetings as it determines are necessary or 
appropriate. 
(2) The Bagley-Keene Open Meeting Act, Article 9 (commencing with Section 11120) of Chapter 1 of Part 
1 of Division 3 of Title 2 of the Government Code, shall apply to all meetings of the ICOC, except as 
otherwise provided in this section. The ICOC shall award all grants, loans, and contracts in public 
meetings and shall adopt all governance, scientific, medical, and regulatory standards in public 
meetings. 
(3) The ICOC may conduct closed sessions as permitted by the Bagley-Keene Open Meeting Act, under 
Section 11126 of the Government Code. In addition, the ICOC may conduct closed sessions when it 
meets to consider or discuss: 
(A) Matters involving information relating to patients or medical subjects, the disclosure of which would 
constitute an unwarranted invasion of personal privacy. 
(B) Matters involving confidential intellectual property or work product, whether patentable or not, 
including, but not limited to, any formula, plan, pattern, process, tool, mechanism, compound, 
procedure, production data, or compilation ofinformation, which is not patented, which is known only 
to certain individuals who are using it to fabricate, produce, or compound an article of trade or a service 
having commercial value and which gives its user an opportunity to obtain a business advantage over 
competitors who do not know it or use it. 
(C) Matters involving prepublication, confidential scientific research or data. 
(D) Matters concerning the appointment, employment, performance, compensation, or dismissal of 
institute officers and employees. Action on compensation of the institute's officers and employees shall 
only be taken in open session. 
(4) The meeting required by paragraph (2) of subdivision (b) of Section 125290.20 shall be deemed to be 
a special meeting for the purposes of Section 11125.4 of the Government Code. 
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(g) Public Records 
(1) The California Public Records Act, Article 1 (commencing with Section 6250) of Chapter 3.5 of 
Division 7 of Title 1 of the Government Code, shall apply to all records of the institute, except as 
otherwise provided in this section. 
(2) Nothing in this section shall be construed to require disclosure of any records that are any of the 
following: 
(A) Personnel, medical, or similar files, the disclosure of which would constitute an unwarranted 
invasion of personal privacy. 
(B) Records containing or reflecting confidential intellectual property or work product, whether 
patentable or not, including, but notlimited to, any formula, plan, pattern, process, tool, mechanism, 
compound, procedure, production data, or compilation ofinformation, which is not patented, which is 
known only to certain individuals who are using it to fabricate, produce, or compound an article of trade 
or a service having commercial value and which gives its user an opportunity to obtain a business 
advantage over competitors who do not know it or use it. 
(C) Prepublication scientific working papers or research data, includinq but not limited to applications 
and proqress reports. 
(3) The institute shall include, in all meeting minutes, a summary of vote tallies and disclosure of each 
board member's votes and recusals on all action items. 
(h) Competitive Bidding 
(1) The institute shall, except as otherwise provided in this section, be governed by the competitive 
bidding requirements applicable to the University of California, as set forth in Article 1 
(commencing with Section 10500) of Chapter 2.1 of Part 2 of Division 2 of the Public Contract Code. 
(3) The requirements of this section shall not be applicable to grants or loans approved by the ICOC. 
(4) Except as provided in this section, the Public Contract Code shall not apply to contracts let by the 
Institute. 
(i) Conflicts oflnterest 
(1) The Political Reform Act, Title 9 (commencing with Section 81000) of the Government Code, shall 
apply to the institute and to the ICOC, except as provided in this section and in subdivision (e) of Section 
125290.50. 
(A) No member of the ICOC shall make, participate in making, or in any way attempt to use his or her 
official position to influence a decision to approve or award a grant, loan, or contract to his or her 
employer, but a member may participate in a decision to approve or award a grant, loan, or contract to 
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an entity in the same field as his or her employer. 
(B) A member of the ICOC may participate in a decision to approve or award a grant, loan, or contract to 
an entity for the purpose of research involving a disease from which a member or his or her 
family suffers or in which the member has an interest as a representative of a disease advocacy 
organization. 
(2) Service as a member of the ICOC by a member of the faculty or administration of any system of the 
University of California shall not, by itself, be deemed to be inconsistent, incompatible, in conflict with, 
orinimical to the duties of the ICOC member as a member of the faculty or administration of any system 
of the University of California and shall not result in the automatic vacation of either such office. Service 
as a member of the ICOC by a representative or employee of a disease advocacy organization, a 
nonprofit academic and research institution, or a life science commercial entity shall not be deemed to 
be inconsistent, incompatible, in conflict with, or inimical to the duties of the ICOC member as a 
representative or employee of that organization, institution, or entity. 
(3) Section 1090 of the Government Code shall not apply to any grant, loan, or contract made by the 
ICOC except where both of the following conditions are met: 
(A) The grant, loan, or contract directly relates to services to be provided by any member of the ICOC or 
the entity the member represents or financially benefits the member or the entity he or she represents. 
(B) The member fails to recuse himself or herself from making, participating in making, or in any way 
attempting to use his or her official position to influence a decision on the grant loan or contract. 
(j) Patent Royalties and License Revenues Paid to the State of California 
(1) The ICOC shall establish standards that require that all grants and loan awards be subject to 
intellectual property agreements that balance the opportunity of the State of California to benefit from 
the patents, royalties, and licenses that result from basic research, therapy development, and clinica 
trials with the need to ensure that essential medical research is not unreasonably hindered by the 
intellectual property agreements. All revenues received through the intellectual property 
agreements established pursuant to this subdivision shall be deposited into an interest-bearinq account 
in the General Fund, and to the extent permitted by law, the amount so deposited and interest thereon 
shr:ill be appropriated for the purpose of offsettinq the costs of providinq treatments and cures arisinq 
from institute-funded research to California patients who have insufficient means to purchase such 
treatment or cure, includinq the reimbursement of patient-qualified costs for research participants. 
(2) These standards shall include, at a minimum, a requirement that CIRM grantees, other than loan 
recipients and facilities grant recipients, share a fraction of the revenue they receive from licensing or 
self-commercializing an invention or technology that arises from research funded by CIRM, as set forth 
below. /\11 rcvcnucs rtctivcd pursuant to this paragraph or regulations adopted to implement this 
paragraph sh,ill be deposited in the General Fund for use consistent with Scction 202(c)(7) of Title 35 of 
thc United Statts Codt, if applic.:iblc. 
(A) (i) A grantee that licenses an invention or technology that arises from o research funded by 
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CIRM, reqardless of the number of qrants awarded to that research proqram, shall pay 25 percent of the 
revenues it receives in excess of five hundred thousand dollars (S500,000), in the aggregate, to the 
General Fund. The threshold amount of five hundred thousand dollars (5500,000) shall be adjusted 
annually by a multiple of a fraction, the denominator of which is the Consumer Price Index, All Urban 
Consumers, All Items (San Francisco-Oakland-San Jose; 1982-84=100) as prepared by the Bureau of 
Labor Statistics of the United States Department of Labor and published for the month of October 2009, 
and the numerator of which is that index published for the month in which the grantee accepts the 
gra nt. For awards made on or after November 5, 2020, the threshold amount of five hundred thousand 
dollars (5>500,000)shall be adiusted annually by a multiple of a fraction, the denominator of which is the 
Consumer Price Index, A// Urban Consumers, A// Items (San Francisco-Oakland-San lose; 1982-84=100) as 
prepared by the Bureau of Labor Statistics of the United States Department of Labor and published for 
the month of October 2020, and the numerator of which is that index published for the month in which 
the qrantee accepts the qrant. 
(ii) If funding sources other than CIRM directly contributed to the development of the invention or 
technology, then the return to the General Fund shall be calculated as follows: The amount of CIRM 
funding for the invention or technology shall be divided by the total of funding provided by all sources, 
and that fraction shall be multiplied by 25. That numeral is the percentage due to the General Fund. 
(B) (i) A grantee that self-commercializes a product that results from an invention or technology that 
arises from research funded by CIRM shall pay an amount to the General Fund equal to three times the 
total amount of the CIRM grant or grants received by the grantee in support of the research that 
contributed to the creation of the product. The rate of payback of the royalty shall be at a rate of 3 
percent of the annual net revenue received by the grantee from the product. 
(ii) In addition to the payment required by clause (i), the first time that net commercial revenues earned 
by the grantee from the product exceed two hundred fifty million dollars (S250,000,000) in a calendar 
year, the grantee shall make a one-time payment to the General Fund equal to three times the total 
amount of the grant or grants awarded by CIRM to the grantee in support of the research that 
contributed to the creation of the product. 
(iii) In addition to the payments required by clauses (i) and (iil the first time that net commercial 
revenues earned by the grantee from the product exceed five hundred million dollars (S500,000,000) in 
a calendar year, the grantee shall make an additional one-time payment to the General Fund equal to 
three times the total amount of the grant or grants awarded by CIRM to the grantee in support of the 
research that contributed to the creation of the product. 
(iv) In addition to the payments required by clauses (il (ii), and (iii), the first time that net commercial 
revenues earned by the grantee from the product equal or exceed five hundred million dollars 
(S500,000,000) in a calendar year, the grantee shall pay the General Fund 1 percent annually of net 
commercial revenue in excess of five hundred million dollars (S500,000,000) for the life of any patent 
covering the invention or technology, if the grantee patented its invention or technology and received a 
CIRM grant or grants amounting to more than five million dollars (S5,000,000) in support of the research 
that contributed to the creation of the product. 
(3) The ICOC shall have the authority to adopt regulations to implement this subdivision. The ICOC shall 
also have the authority to modify the formulas specified in subparagraphs (A) and (B) of paragraph (2) 
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Amended 11.18.19 
through regulations if the ICOC determines pursuant to paragraph (1) that a modification is required 
either in order to ensure that essential medical research, including, but not limited to, therapy 
development and the broad delivery of therapies to patients, is not unreasonably hindered, or to ensure 
that the State of California has an opportunity to benefit from the patents, royalties, and licenses that 
result from basic research, therapy development, and clinical trials. The ICOC shall notify the 
appropriate fiscal and policy committees of the Legislature 10 calendar days before exercising its 
authority to vote on the modification of the formulas specified in subparagraphs (A) and (B) of 
paragraph (2). The amendments made to this subdivision (i) are not intended to affect the institute's 
authority to modify the provisions set forth in this subdivision (i) pursuant to this paraqraph, includinq 
but not limited to any modifications that occurred prior to the effective date of the Initiative amendinq 
this subdivision. 
(k) Preference for California Suppliers 
The ICOC shall establish standards to ensure that grantees purchase goods and services from California 
suppliers to the extent reasonably possible, in a good faith effort to achieve a goal of more than SO 
percent of such purchases from California suppliers. 
(l) Additional Accountability Requirements 
To assure strict accountability and transparency, includinq riqorous conflict of interest rules, ethical 
research and treatment standards, and independent financial audits, every four years the ICOCshall 
update, at its discretion, the standards relatinq to conflict of interest rules, ethical research and 
treatment, and independent financial audits, to be qenerally aliqned with standards adopted by the 
National Academy of Sciences to the extent that such standards are consistent with constitutional and 
statutory requirements r:ipplicable to the institute. 
SEC. 11. Section 125290.35 of the Health and Safety Code is hereby amended to read as follows: 
125290.35. Medical and Scientific Accountability Standards. 
(a) Medical Standards 
In order to avoid duplication or conflicts in technical standards for scientific and medical research, with 
alternative state programs, the institute will develop its own scientific and medical standards to carry 
out the specific controls and intent of the act, notwithstanding subdivision (b) of Section Scctions 
125300, 125320, 125118, 125119, 125119.3 and 125119.5, or any other current or 
future state laws or regulations dealing with the study and research of pluripotent stem cells and/or 
progenitor cells, or other vital research opportunities, except Section 125315. The ICOC, its working 
committees, and its grantees shall be governed solely by the provisions of this act in the establishment 
of standards, the award of grants and the conduct of grants awarded pursuant to this act. 
(b) The ICOC shall establish standards as follows: 
(1) Informed Consent 
Standards for obtaining the informed consent of research donors, patients, or participants, which 
initially shall be generally based on the standards in place on January 1, 2003, for all research funded by 
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Amended 11.18.19 
the National Institutes of Health, with modifications to adapt to the mission and objectives of the 
institute. 
(2) Controls on Research Involving Humans 
Standards for the review of research involving human subjects which initially shall be generally based on 
the Institutional Review Board standards promulgated by the National Institutes of Health and in effect 
on January 1, 2003, with modifications to adapt to the mission and objectives of the institute. 
(3) Prohibition on Compensation 
Standards prohibiting compensation to research donors or participants, while permitting 
reimbursement of expenses. 
(4) Permitted Reimbursement 
Standards permittinq reimbursement for expenses, which shall include but not be limited to medical 
expenses and lodqinq, meals, and travel expenses for research participants and careqivers in order to 
ensure functional access to clinical trials. For purposes of this paraqraph, "careqivers" includes family 
members, friends, and professional careqivers providinq supportive care. 
(4) (fl Patient Privacy Laws 
Standards to assure compliance with state and federal patient privacy laws. 
J,!d{fl Limitations on Payments for Cells 
Standards limiting payments for the purchase of stem cells or stem cell lines to reasonable payment for 
the removal, processing, disposal, preservation, quality control, storage, transplantation, or 
implantation or legal costs or other administrative costs associated with these medical procedures and 
specifically including any required payments for medical or scientific technologies, products, or 
processes for royalties, patent, or licensing fees or other costs for intellectual property. 
% Time Limits for Obtaining Cells 
Standards setting a limit on the time during which cells may be extracted from blastocysts, which shall 
initially be 8 to 12 days after cell division begins, not counting any time during which the blastocysts 
and/or cells have been stored frozen. 
(8) Standards for Genetic Medical Treatments and Research 
Standards for research involvinq qenetic medical treatments which shall, in the ICOC's discretion, 
qenerally be based on the standards adopted by the National Academy of Sciences. 
SEC. 12. Section 125290.40 of the Health and Safety Code is hereby amended to read as follows: 
125290.40. ICOC Functions. 
The ICOC shall perform the following functions: 
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(a) Oversee the operations of the institute. 
(b) Develop annual and long-term strategic research and financial plans for the institute. 
(c) Make final decisions on research standards and grant awards in California across the research and 
therapy development and delivery spectrum, from stem cell discovery research and early development to 
clinical trials and therapy delivery. 
(d) Ensure the completion of an annual financial audit of the institute's operations. 
(e) Issue public reports on the activities of the institute. 
(f) Develop and implement proqrams to enhance patient access to affordable stem cell and related 
treatments and cures throuqh public hospitals and clinics and policies regarding 
intellectual property rights arising from research funded by the institute. 
(q) Establish and oversee the institute's research, therapy development, and therapy delivery proqrams, 
includinq but not limited to the Alpha Stem Cell Clinics and Community Care Centers of Excellence, 
traininq and fellowship, and shared research laboratory proqrams. 
(h) Establish and oversee the development of policies and proqrams to help make treatments r:ind cures 
arisinq from institute-funded research availr:ible and affordable for California patients, throuqh 
enqaqement with healthcare providers, research and therapy development institutions, businesses, 
qovernmental aqencies, philanthropists, foundations, and patient advocacy qroups, and based on 
recommendations made by the Treatments and Cures Accessibility and Affordability Workinq Group. 
(-g){il Establish rules and guidelines for the operation of the ICOC and its working groups. 
% {il Perform all other acts necessary or appropriate in the exercise of its power, authority, and 
jurisdiction over the institute. 
p JSelect members of the working groups. 
ffl Adopt, amend, and rescind rules and regulations to carry out the purposes and provisions of this 
chapter, and to govern the procedures of the ICOC. Except as provided in subdivision (km), these rules 
and regulations shall be adopted in accordance with the Administrative Procedure Act (Government 
Code, Title 2, Division 3, Part 1, Chapter 4.;> 3.5 Sections .143-74 11340 et seq.). 
J,k4{ Notwithstanding the Administrative Procedure Act (APA), and in order to facilitate the immediate 
commencement of research covered by this chapter, the ICOC may adopt interim regulations without 
compliance with the procedures set forth in the APA. The interim regulations shall remain in effect for 
270 days unless earlier superseded by regulations adopted pursuant to the APA. For purposes of 
subdivision (l), requests for applications, proqram announcements, and notices of award shall not be 
considered requlations. 
p (z;4Request the issuance of bonds from the California Stem Cell Research and Cures Finance 
Committee and loans from the Pooled Money Investment Board. 
j {gl May annually modify its funding and finance programs to optimize the institute's ability to 
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achieve the objective that its activities be revenue-positive for the State of California during its first five 
years of operation without jeopardizing the progress of its core medical and scientific research program. 
W {pl Notwithstanding Section 11005 of the Government Code, accept additional revenue and real and 
personal property, including, but not limited to, gifts, royalties, interest, and appropriations that may be 
used to supplement annual research grant funding and the operations of the institute. 
(q) Subiect to the restrictions set forth in this article, develop conflict of interest standards, and at its 
discretion, consult with the National Academy of Sciences and the Scientific and Medical Accountability 
Standards Workinq Group, for the consideration of fundinq awards based on best practices established 
by the National Academies of Sciences to prevent conflicts of interest in the award of research fundinq 
and update those standards no less than every four years to be, at the ICOC's discretion, qenerally 
aliqned with standards adopted by the National Academies of Sciences, subiect to the constitutional and 
statutory requirements applicable to the institute. 
SEC. 13. Section 125290.45 of the Health and Safety Code is hereby amended as follows: 
125290.45. ICOC Operations. 
(a) Legal Actions and Liability 
(1) The institute may sue and be sued. 
(2) Based upon ICOC standards, institute grantees shall indemnify or insure and hold the institute 
harmless against any and all losses, claims, damages, expenses, or liabilities, including attorneys' fees, 
arising from research conducted by the grantee pursuant to the grant, and/or, in the alternative, 
grantees shall name the institute as an additional insured and submit proof of such insurance. 
(3) Given the scientific, medical, and technical nature of the issues facing the ICOC, and notwithstanding 
Section 11042 of the Government Code, the institute is authorized to retain outside counsel when the 
ICOC determines that the institute requires specialized services not provided by the Attorney General's 
office. 
(4) The institute may enter into any contracts or obligations which are authorized or permitted by law. 
(b) Personnel 
(1) The ICOC shall from time to time determine the total number of authorized employees for the 
institute, which numbershall not exceed 70 employees (full time equivalentl excluding members of the 
working groups and members of the ICOC who shall not be considered institute employeesand 
excludinq up to 15 additional institute employees (full time equivalent) to support the development of 
policies and proqrams to help make treatments and cures arisinq from institute-funded research 
available and affordable for Californians. The cap on employees shall not apply to employees funded 
throuqh sources other than bond proceeds or the General Fund. The ICOC shall select a chairperson, vice 
chairperson and president who shall exercise all of the powers delegated to them by the ICOC. The 
following functions apply to the chairperson, vice chairperson and president: 
(A) The chairperson's primary responsibilities are to manage the ICOC agenda and workflow including all 
evaluations and approvals of scientific and medical working group grants, loans, facilities, and standards 
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evaluations, and to supervise all annual reports and public accountability requirements; to manage and 
optimize the institute's bond financing plans and funding cashflow plan; to interface with the California 
Legislature, the United States Congress, the California health care system, and the California public; to 
optimize all financial leverage opportunities for the institute, includinq without limitation qeneratinq 
matchinq or supplemental funds throuqh collaborations with other states, nations, territories, or 
institutions' and to lead negotiations for intellectual property agreements, policies, and contract terms. 
The Chairperson shall also serve as a member of the Treatments and Cures Accessibility and Affordability 
Workinq Group, the Scientific and Medical Accountability Standards Working Group and the Scientific 
and Medical Research Facilities Working Group and as an ex officio member of the Scientific and 
Medical Research Funding Working Group. The Vice Chairperson's primary responsibilities are to 
support the Chairperson in all duties and to carry out those duties in the Chairperson's absence. 
(B) The president's primary responsibilities are to serve as the Chief Executive of the institute; to recruit 
the highest scientific and medical talent in the United States to serve the institute on its working groups; 
to serve the institute on its working groups; to direct ICOC staff and participate in the process of 
supporting all working group requirements to develop recommendations on grants, loans, facilities, and 
standards as well as to direct and support the ICOC process of evaluating and acting on those 
recommendations, the implementation of all decisions on these and general matters of the ICOC; to 
hire, direct, and manage the staff of the institute; to develop the budgets and cost control programs of 
the institute; to manage compliance with all rules and regulations of the ICOC, including the 
performance of all grant recipients; and to manage and execute all intellectual property agreements and 
any other contracts pertaining to the institute or research it funds. 
(2) Each member of the ICOC except, the chairperson, vice chairperson, and the members 
appointed pursuant to paraqraphs (3), (4), (5), and (6) of subdivision (a) of Section 125290.20 who shall 
be compensated pursuant to paraqraph (3), shall receive a per diem of one hundred dollars (SIOO) per 
day (adjusted annually for cost of living) for each day actually spent in the discharge of the member's 
duties, plus reasonable and necessary travel and other expenses incurred in the performance of the 
member's duties. 
(3) The ICOC shall establish daily consulting rates and expense reimbursement standards for the 
members of all of its working groups, includinq the members of the ICOC appointed pursuant to 
paraqraphs (3), (4), (5), and (6) of subdivision (a) of Section 125290.20. The daily consultinq rate shall 
include time spent in preparation for, and participation in, institute, workinq qroup, and ICOC meetinqs 
and shall include compensation and expense reimbursement for careqivers when necessary to facilitate a 
membeYs participation in a meetinq as a result of the membeYs medical condition. 
(4) Notwithstanding Section 19825 of the Government Code, the ICOC shall set compensation for the 
chairperson, vice chairperson, and president and other officers, and for the scientific, medical, technical, 
and administrative staff of the institute within the range of compensation levels for executive officers 
and scientific, medical, technical, and administrative staff of medical schools within the University of 
California system and the nonprofit academic and research institutions described in paragraph (2) of 
subdivision (a) of Section 125290.20, and travel expense reimbursement rates and movinq and 
relocation expense limits. 
5EC. 14. Section 125290.50 of the Health and Safety Code is hereby amended as follows: 
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125290.50. Scientific and Medical Working Groups - General. 
(a) The institute shall have, and there is hereby established f3y7 separate scientific and medical 
working groups as follows: 
(1) Scientific and Medical Research Funding Working Group. 
(2) Scientific and Medical Accountability Standards Working Group. a-rA 
(3) Scientific and Medical Research Facilities Working Group. 
(4) Treatments and Cures Accessibility and Affordability Workinq Group. 
(b) Working Group Members 
lAppointments of scientific and medical working group members shall be made by a majority vote of 
a quorum of the ICOC, within 30 days of the election and appointment of the initial ICOC members. The 
working group members" terms shall be six years except that, after the first six-year terms, the 
members" terms will be staggered so that one-third of the members shall be elected for a term that 
expires two years later, one-third of the members shall be elected for a term that expires four years 
later, and one-third of the members shall be elected for a term that expires six years later. Subsequent 
terms are for six years. Working group members may serve a maximum of two consecutive termsL 
provided that the ICOC may, by a two-thirds vote of a quorum, reappoint non-ICOC workinq qroup 
members to serve more than two consecutive terms. 
(2) Appointments of members of the Treatments and Cures Accessibility and Affordability Workinq Group 
shall be made by a maiority vote of a quorum of the ICOC, within 90 days of the effective date of the 
Initiative addinq this paraqraph. The workinq qroup members' terms shall be six years, and members 
may serve a maximum of two consecutive terms, provided that the ICOCmay, by a two-thirds vote of a 
quorum, reappoint non-ICOC workinq qroup members to serve more than two consecutive terms. 
(3) The ICOC may appoint ad hoc votinq members to each workinq qroup as necessary to obtain 
expertise for a particular expert review session, not to exceed three members for any one expert review 
session. 
(c) Working Group Meetings 
Each scicntific and medical working group shall hold at least four meetings per year, one of which shall 
be designated as its annual meeting, except as otherwise determined by the institute. 
(d) Working Group Recommendations to the ICOC 
Recommendations of each the working groups may be forwarded to the ICOC only by a vote of 
a majority of a quorum of the members of each panel for that working group. If 35 percent of the 
members of any working group panel award scores in the fundinq ranqe, a minority recommendr:ition 
report, includinq o summary of the strenqths and weaknesses of the application and a rebuttal to the 
maiority recommendation, shall may be submitted to the ICOC. The ICOC shall consider the 
recommendations of the working groups in making its decisions on applications for research and facility 
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grants and loan awards and in adopting regulatory standards and policies and proqrams. Each working 
group shall recommend to ICOC rules, procedures, and practices for that working group. 
(e) Conflict of Interest 
(l) The ICOC shall adopt conflict ofinterest rules, based on standards applicable to members of 
scientific review committees of the National Institutes of Health, to govern the participation of non-ICOC 
working group members. 
(2) The ICOC shall appoint an ethics officer from among the staff of the institute. 
(3) Because the working groups are purely advisory and have no final decisionmaking authority, 
members of the working groups shall not be considered public officials, employees, or consultants for 
purposes of the Political Reform Act (Title 9 (commencing with Section 81000) of the Government 
Code) Sections 1090 and 19990 of the Government Code, and Sections 10516 and 10517 of the Public 
Contract Code. 
(f) Working Group Records 
All records of the working groups submitted as part of the working groups" recommendations to the 
ICOC for approval shall be subject to the Public Records Act. Except as provided in this subdivision, the 
working groups shall not be subject to the provisions of Article 9 (commencing with Section 11120) of 
Chapter 1 of Part I of Division 3 of Title 2 of the Government Code, or Article 1 (commencing with 
Section 6250) of Chapter 3.5 of Division 7 of Title 1 of the Government Code. 
SEC. 15. Section 125290.55 of the Health and Safety Code is hereby amended as follows: 
125290.55. Scientific and Medical Accountability Standards Working Group. 
(a) Membership 
The Scientific and Medical Accountability Standards Working Group shall have 19 members as follows: 
(1) Five ICOC members from the 10 groups that focus on disease-specific areas described in paragraphs 
(3), (4), and (5) of subdivision (a) of Section 125290.20 or from the members appointed pursuant to 
pamqraph (6) ofsubdivision (a) ofSection 125290.20. 
(2) Nine scientists and clinicians nationally recognized in the field of pluripotent and progenitor cell 
research. 
(3) Four medical ethicists. 
(4) The Chairperson of the ICOC. 
(b) Functions 
The Scientific and Medical Accountability Standards Working Group shall have the following functions: 
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(1) To recommend to the ICOC scientific, medical, and ethical standards. 
(2) To recommend to the ICOC standards for all medical, socioeconomic, and financial aspects of clinical 
trials and therapy delivery to patients, including, among others, standards for safe and ethical 
procedures for obtaining materials and cells for research and clinical efforts for the appropriate 
treatment of human subjects in medical research consistent with paragraph (2) of subdivision (b) of 
Section 125290.35, and to ensure compliance with patient privacy laws. 
(3) To recommend to the ICOC modification of the standards described in paragraphs (1) and (2) as 
needed. 
(4) To mal<e recommendations to the ICOC on the oversight of funded research to ensure compliance 
with the standards described in paragraphs (1) and (2). 
(5) To advise the ICOC, the Scientific and Medical Research Funding Working Group, and the Scientific 
and Medical Research Facilities Working Group, on an ongoing basis, on relevant ethical and regulatory 
issues. 
SEC. 16. Section 125290.60 of the Health and Safety Code is hereby amended to read as follows: 
125290.60. Scientific and Medical Research Funding Working Group. 
(a) Membership 
The Scientific and Medical Research Funding Working Group shall have at least 23 members as follows: 
(1) Seven ICOC members from the -IG)12 disease advocacy group members described in paragraphs (3), 
(4), and (5) of subdivision (a) of Section125290.20 or the members described in paraqraph (6) of 
subdivision (a) ofSection 125290.20. 
(2) At least 15 scientists nationally recognized in the field of stem cell research or other vital research 
opportunities, 15 of whom shall be desiqnated to serve on each expert review pr:inel. 
(3) The Chairperson of the ICOC. 
(b) Functions 
The Scientific and Medical Research Funding Working Group shall perform the following functions: 
(1) Recommend to the ICOC interim and final criteria, standards, and requirements for considering 
funding applications and for awarding research grants and loans. 
(2) Recommend to the ICOC standards for the scientific and medical oversight of awards. 
(3) Recommend to the ICOC any modifications of the criteria, standards, and requirements described in 
paragraphs (1) and (2) above as needed. 
(4) Review grant and loan applications based on the criteria, requirements, and standards adopted by 
the ICOC and make recommendations to the ICOC for the award of research, therapy development, ,mA 
clinical trial, and therapy delivery grants and loans. 
23 
              
               
                 
           
              
      
               
   
          
               
                
  
              
             
      
                
                
             
               
              
            
                
                 
                  
              
               
     
               
                  
              
Amended 11.18.19 
(5) Conduct expert peer review r:ind progress oversight reviews of grantees to ensure 
compliance with the terms of the award, and report to the ICOC any recommendations for subsequent 
action. 
(6) Recommend to the ICOC standards for the evaluation of grantees to ensure that they comply with all 
applicable requirements. Such standards shall mandate periodic reporting by grantees and shall 
authorize the Scientific and Medical Research Funding Working Group to audit a grantee and forward 
any recommendations for action to the ICOC. 
(7) Recommend its first grant awards within 60 days of the issuance of the interim standards. 
(c) Recommendations for Awards 
Award recommendations shall be based upon a competitive evaluation as follows: 
(1) A demonstrated record of achievement in the areas of pluripotent stem cell and progenitor cell 
biology and medicing unltss the rcrcarch is dtttrmincd to be a Vital Rcscarch OpportunityL or in other 
vital research opportunities. 
(2) The quality of the research proposal, the potential for achieving significant research, or clinical 
results, the timetable for realizing such significant results, the importance of the research objectives, 
and the innovativeness of the proposed research. 
(3) In order to ensure that institute funding does not duplicate or supplant existing funding, a high 
priority shall be placed on funding pluripotent stem cell and progenitor cell research that cannot, or is 
unlikely to, receive timely or sufficient federal funding, unencumbered by limitations that would impede 
the research. In this regard, other research categories funded by the National Institutes of Health shall 
not be funded by the institute, unless such research fundinq is not timely or sufficient. 
(4) Notwithstanding paragraph (3), other scientific and medical research and technologies and/or any 
stem cell research proposal not actually funded by the institute under paragraph (3) may be funded by 
the institute if at least two-thirds of a quorum of the members of the Scientific and Medical Research 
Funding Working Group recommend to the ICOC,or if a maiority of a quorum of the members of the 
ICOC determine, that such a research proposal is a Vital P,cscarch Opportunity vital research opportunity. 
SEC. 17. Section 125290.70.5 is added to the Health and Safety Code to read as follows: 
125290.70.5. Appropriation and Allocation of Fundinq. 
(a) Monies in the California Stem Cell Research and Cures Fund shall be allocated as follows: 
(1) (A) No less than ninety-five and one half percent (95.5%) of the proceeds of the bonds authorized 
pursuant to Section 125291.110, net of bond proceeds allocated to purposes described in paraqraphs (4) 
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and (5) ofsubdivision (a) of Section 125291.100, shall be used for qrants and qrant oversiqht C7Sprovided 
in this chapter. 
(B) Not less than 98 percent (98%) of the proceeds of bonds used for qrants shall be used for research, 
therapy development, and therapy delivery qrants, with no more than the followinq amounts-as 
stipulated below - to be committed durinq the first ten years followinq the effective date of the Initiative 
addinq this subparaqraph, with each yeaYs fundinq commitments to be advanced over a period of one to 
seven years, except that any such funds that are not committed may be carried over to one or more 
followinq years. The maximum amount of research fundinq to be allocated annually is as follows: Year1, 
11%; Year 2, 11%; Years 3 throuqh 10, 9%; and Year Il and each year thereafter, 6% cumulatively. To 
accomplish the qoals ofSection 125290.75, up to two percent (2%) of the amount available for qrants 
may be used for research consultinq in support of access to, and the r:iffordability of, treatments and 
cures arisinq from institute-funded research and therapy development and delivery, as determined by the 
Governinq Board of the institute based on the recommendations of the Treatments and Cures 
Accessibility and Affordability Workinq Group and the President. 
(C) Not more than three percent (3%) of the proceeds of bonds authorized by Section 125291.110 may be 
used by the institute for research and research facilities implementation costs, includinq the 
development, administration and oversiqht of the qrant-makinq process. 
(2) (A) Not more than three and one half percent (3.5%) of the proceeds of the bonds authorized 
pursuant to Section 125291.110 shall be used for the costs of qeneral administration of the Institute. 
(B) Not more than one percent (1%) of the proceeds of the bonds authorized pursuant to Section 
125291.110 may be used by the institute to pay for the costs of up to 15 full time employees over ten to 
15 or more years, includinq but not limited to administrative support, facilities costs, salary, benefits, 
tmvel reimbursement, and meetinq costs, to support the work of the institute to develop policies and 
proqrams to help Californians obtain access to human clinical trials, therapies, mitiqatinq treatments, 
and cures arisinq from institute-funded research and to promote the accessibility and affordability of 
such human clinical trials, treatments, and cures for Californians. 
(3) In any sinqle year any new research fundinq to any sinqle qrantee [or any proqram year is limited to 
no more than one percent (1%) of the total bonds authorized pursuant to Section 125291.110. This 
limitation shall be considered separately for each new proposal without aqqreqatinq any prior year 
approvals that may fund research activities. This requirement shall be determinative, unless 65 percent 
of a quorum of the ICOC approves a hiqher limit for that qrantee. 
(4) Up to one and one half percent (1.5%) of the proceeds of the bonds authorized pursuant to Section 
125291.110, net of costs described in paraqraphs (2), (4) and (5) ofsubdivision (a) ofSection 125291.100 
shall be allocated for qrants to build, equip, or fund operations of Community Care Centers of Excellence 
and up to one half o7 one percent (0.5%) shall be allocated to build or equip Shared Labs, which are 
intended to be operational in the first five years 7ollowinq the effective date of the Initiative addinq this 
Section. Fundinq received by a qrantee from an institute award for construction shall be subiect to 
prevailinq waqe laws. 
(5) The institute shall limit indirect costs to no more than 25 percent (25%) of a research award, 
excludinq amounts included in a facilities awr:ird, except that the indirect cost limitation may be 
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increased by that amount by which the qrantee provides matchinq funds in excess of 20 percent (20%) of 
the qrant amount. 
(b) The institute's fundinq schedule is desiqned to create a positive tax revenue stream for the state of 
California durinq the first five calendar years followinq the voters' approval of the initiative addinq this 
section, without drawinq funds from the state qeneral fund for principal and interest payments for those 
first five calendar years. 
(c) The institute shall allocate at least 5L5 billion of the proceeds of the bonds authorized pursuant to 
Section 125291.110 to make qrr:ints for research, therapy development, and thempy delivery involvinq 
diseases and conditions of the brain and central nervous system, includinq but not limited to AlzheimeYs 
disease, Parkinson's disease, stroke, dementia, epilepsy, schizophrenia, depression, traumatic brain 
iniury, brain cancer, and autism, and for qrant oversiqht and qeneral administration costs associated 
with such qrants and loans, subject to the limits in subparaqraph (C) of paraqraph (1) of subdivision (a) 
of this Section and in subparaqraph (A) of paraqraph (2) of subdivision (a) of this Section. 
(d) The allocation of the proceeds of bonds authorized pursuant to Section 125291.30 shall continue to 
be qoverned by Section 125290. 70. 
SEC. 18. Section 125291.15 of the Health and Safety Code is hereby amended to read as follows: 
(a) "Act" means the California Stem Cell Research and Cures Bond Actconstituting Chapter 3 
(commencing with Section 125290.10) of Part 5 of Division 106. 
(b) "Board" or "institute" means the California Institute for Regenerative Medicine designated in 
accordance with subdivision (b) of Section 125291.40. 
(c) "Committee" means the California Stem Cell Research and Cures Finance Committee created 
pursuant to subdivision (a) of Section 125291.40. 
(d) "Fund" means the California Stem Cell Research and Cures Fund created pursuant to Section 
125291.25. 
(e) "Interim debt" means any interim loans pursuant to subdivision (b) of Section 125290.70, and 
Sections 125291.60 and 125291.65, bond anticipation notes or commercial paper notes issued to make 
deposits into the fund and which will be paid from the proceeds of bonds issued pursuant to this article. 
SEC. 19. Section 125291.35 of the Health and Safety Code is hereby amended to read as follows: 
125291.35. The bonds authorized by Artide 2 shall be prepared, executed, issued, sold, paid, 
and redeemed as provided in the State General Obligation Bond Law (Chapter 4 (commencing with 
Section 16720) of Part 3 of Division 4 of Title 2 of the Government Code), and all of the provisions of that 
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law, as amended from time to time, except subdivisions (a) and (b) of Section 16727 apply to the bonds 
and to this article and are hereby incorporated in this article as though set forth in full in this article. 
SEC. 20. Section 125291.60 of the Health and Safety Code is hereby amended to read as follows: 
125291.60. For the purpose of carryinq out Article 2, The the Director of Finance may authorize the 
withdrawal from the General Fund of an amount or amounts, not to exceed the amount of the unsold 
bonds that have been authorized by the committee, to be sold for the purpose of carrying out this 
article excludinq any refundinq bonds authorized pursuant to section 125291. 75, less any amount loaned 
pursuant to section 125291.65 and not yet repaid, and any amount withdrawn from the General Fund 
pursuant to this Section and not yet returned to the General Fund. Any amount withdrawn shall be 
deposited in the fund. Any money made available under this section shall be returned to the General 
Fund, plus an amount equal to the interest that the money would have earned in the Pooled Money 
Investment Account, from money received from the sale of bonds for the purpose of carrying out this 
article. 
SEC. 21. Section 125291.65 of the Health and Safety Code is hereby amended to read as follows: 
125291.65. The institute may request the Pooled Money Investment Board to make a loan from the 
Pooled Money Investment Account in accordance with Section 16312 of the Government Code for the 
purposes of carrying out Artide 2, excludinq any refundinq bonds authorized pursuant to 
section 125291. 75, less any amount loaned pursuant to this section and not yet repaid, and any amount 
withdrawn from the General Fund pursuant to Section 125291.60 and not yet returned to the General 
Fund. The amount of the request shall not exceed the amount of the unsold bonds that the committee, 
by resolution, has authorized to be sold for the purpose of carrying out this article. The institute shall 
execute any documents required by the Pooled Money Investment Board to obtain and repay the loan. 
Any amounts loaned shall be deposited in the fund to be allocated by the institute in accordance with 
this article. 
SEC. 22. Section 125291.70 of the Health and Safety Code is hereby amended to read as follows: 
125291.70. All money deposited in the fund that is derived from premium and accrued interest on 
bonds sold shall be reserved in the fund and shall be available for transfer to the General Fund as a 
credit to expenditures for bond interest, except that amounts derived from premium may be reserved 
and used to pay costs of issuance prior to any transfer to the General Fund. 
SEC. 23. Section 125291.75 of the Health and Safety Code is hereby amended to read as follows: 
125291.75. The bonds issued and sold pursuant to Artide 2 may be refunded in accordance with Article 
6 (commencing with Section 16780) of Chapter 4 of Part 3 of Division 4 of Title 2 of the Government Code, 
which is a part of the State General Obligation Bond Law. Approval by the voters of the state for the 
issuance of the bonds described in this article includes the approval of the issuance of any bonds issued 
to refund any bonds originally issued under this article or any previously issued refunding bonds. 
refunded with the proceeds of refundinq bonds as authorized by this section may be leqally defeased to 
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the extent permitted by law in the mr:inner and to the extent set forth in the resolution, as amended from 
time to time, r:iuthorizinq that refunded bond. 
SEC. 24. Article 2.5 is added to Chapter 3 of Part 5 of Division 106 to the Health and Safety Code to 
read as follows: 
ARTICLE2.5. California Stem Cell Research, Treatments, and Cures Bond Act of 2020 
125291.90. This artide shall be known, and may be cited, as the California Stem Cell Research, 
Trer:itments, and Cures Bond Act of 2020. 
125291.95. As used in Artide 2.5, the followinq terms have the followinq meaninq: 
(a)"Act" means the California Stem Cell Research and Cures Act constitutinq Chapter 3 (commencinq 
with Section 125290.10) of Part 5 of Division 106, as amended by the California Stem Cell Research, 
Treatments, and Cures Initiative of 2020. 
(b) "Board" or"Institute" means the California Institute for Reqenerative Medicine desiqnated in 
accordance with subdivision (b) of Section 125291.120. 
(c) "Committee" means the California Stem Cell Research and Cures Finance Committee created pursuant 
to subdivision (a) of Section 125291.40 and desiqnated in accordance with subdivision (a) of Section 
125291.120. 
(d)"Fund" means the California Stem Cel) Research, Treatments, and Cures Fund of 2020 created 
pursuant to Section 125291.105. 
(e)"Interim debt" means any interim loans pursuant to Sections 125291.140 and 125291.145, bond 
anticipation notes or commercial paper notes issued to make deposits into the fund and which will be 
paid from the proceeds of bonds issued pursuant to this article. 
125291.100. (a) Notwithstandinq Section 13340 of the Government Code or any other provision of law, 
moneys in the fund are appropriated without reqard to fiscal years to the institute for the purpose of (1) 
makinq qrants or loans to fund research and construct facilities for research, all as described in and 
pursuant to Section 125290. 70.5, (2) payinq qeneral administrative costs of the institute (not to exceed 
three and one half percent (3.5%) in accordance with subparaqraph (A) of paraqraph (2) of subdivision 
(a) of Section 125290. 70.5), (3) payinq the annual administration costs of any interim debt or bonds after 
December 31 of the fifth full calendar year after this Section takes effect, (4) payinq the costs of issuinq 
interim debt, payinq the annual administration costs of the interim debt until and includinq December 31 
of the fifth full calendar year after this Section takes effect, and payinq interest on interim debt, if such 
interim debt is incurred or issued on or prior to December 31 of the fifth full calendar year after this 
Section takes effect, and (5) payinq the costs of issuinq bonds, payinq the annual administration costs of 
the bonds until and includinq December 31 of the fifth full calendar year after this Section takes effect, 
and payinq interest on bonds that accrues on or prior to December 31 of the fifth full calendar year after 
this Section takes effect (except that such limitation does not apply to premium and accrued interest as 
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provided in Section 125291.150). In addition, moneys in the fund or other proceeds of the sale of bonds 
authorized by this article may be used to pay principal of, redemption price (includinq accrued interest), 
or premium on any interim debt issued prior to the initial issuance of bonds authorized by this article. 
Moneys deposited in the Fund from the proceeds of interim debt may be used to pay qeneral 
administrative costs of the Institute without reqard to the three and one half percent (3.5%) limit set 
forth in (ii) above, so lonq as such three and one half percent (3.5%) limit is wtisfied for each issue of 
bonds. 
(b) Repayment of principal and interest on any loans made by the Institute pursur:int to this article shall 
be deposited in the fund and used for the purposes of Section 125290. 70.5, includinq the Institute's 
administrative costs, or for payinq continuinq costs of the annual administration of outstandinq bonds. 
125291.105. The proceeds of interim debt and bonds issued and sold pursuant to this article shall be 
deposited in the State Treasury to the credit of the California Stem Cell Research and Cures Fund of 2020, 
which is hereby created in the State Treasury, except to the extent that proceeds of the issuance of bonds 
are used directly to repay interim debt. 
125291.110. Bonds in the total amount of five billion and five hundred million dollars (55,500,000,000), 
not includinq the amount of any refundinq bonds issued in accordance with Section 125291.155, or as 
much thereof as is necessary, may be issued and sold to provide a fund to be used for carryinq out the 
purposes expressed in this article and to be used and sold for carryinq out the purposes of Section 
125291.100 and to reimburse the General Obliqation Bond Expense Revolvinq Fund pursuant to Section 
16724.5 of the Government Code. The bonds, when sold, shall be and shall constitute a valid and bindinq 
obliqation o[ the State of California, and the full faith and credit of the State of California is hereby 
pledqed for the punctual payment of both the principal of, and interest on, the bonds as the principal and 
interest become due and payable. 
125291.115. The bonds authorized by this article shall be prepared, executed, issued, sold, paid, and 
redeemed as provided in the State General Obliqation Bond Law (Chapter 4 (commencinq with Section 
16720) of Part 3 of Division 4 of Title 2 of the Government Codel and all of the provisions of that law, as 
amended from time to time, except subdivisions (a) and (b) of Section 16727 apply to the bonds and to 
this article and are hereby incorporated in this article as thouqh set forth in full in this article. 
125291.120. (a) Solely for the purpose of authorizinq the issuance and sale, pursur:int to the State 
General Obliqation Bond Law, of the bonds and interim debt authorized by the article, the California 
Stem Cell Research and Cures Finance Committee, established pursuant to Section 125291.40, is hereby 
desiqnated as "the committee" as that term is used in the State General Obliqation Bond Law. 
(b) For purposes of the State General Obliqation Bond Law, the California Institute for Reqenerative 
Medicine Governinq Board is desiqnated the"board." 
125291.125. (a) The committee shall determine whether or not it is necessary or desirable to issue bonds 
authorized pursuant to this article in order to carry out the actions specified in this article and, if so, the 
amountofbondstobeissuedandsold. TheTreasurershallusereasonableeffortstosellbondswith 
pricinq at par or better and to pay the issuance costs out of premium if reasonably achievable and in the 
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best interests of the state, at the TreasureYs discretion. Successive issues of bonds may be authorized 
and sold to carry out those actions proqressively, and it is not necessary that all of the bonds authorized 
to be issued be sold r:it any one time. The bonds may bear interest, which is includable in qross income 
for federal income tax purposes if the committee determines that such treatment is necessary in order to 
provide funds for the purposes of the act. The costs of each bond issue sold on or after the sixty-first 
month after this article takes effect shall be at the discretion of the Treasurer, and may be amortized 
over or up to o forty-year period. 
(b) The total amount of the bonds r:iuthorized by Section 125291.110 that mr:iy be issued in any calendar 
year, commencinq in 2021, shall not exceed a cumulative averaqe of five hundred and forty million 
dollars (';540,000,000). If less than this amount of bonds is issued in any year, the remaininq permitted 
amount may be carried over to one or more subsequent years. Pursuant to Section 125291.140, the 
Director of Finance may, in the DirectoYs discretion, authorize a loan from the General Fund to the 
Institute on or after the effective date of this article. 
(c) Until December 31 of the fifth full calendar year after this section becomes effective, all interest on 
any interim debt or bonds issued under this article will be paid from proceeds from the sale of 
such interim debt or bonds in accordance with the obiective of this Initiative of avoidinq any debt service 
payments by the General Fund (both principal and interest) durinq the initial period of basic research and 
therapy development followinq the effective date of this section. 
125291.130. There shall be collected each year and in the same manner and at the same time C7S other 
state revenue is collected, in addition to the ordinary revenues of the state, a sum in an amount required 
to pay the principal of, and interest on, the bonds becominq due each year. It is the duty of all officers 
charqed by law with any duty in reqard to the collection of the revenue to do and perform each and 
every act that is necessary to collect that additional sum. 
125291.135. Notwithstandinq Section 13340 of the Government Code, there is hereby appropriated 
from the General Fund in the State Treasury, for the purposes of this article, an amount that will equal 
the total of the followinq: 
(a) The sum annually necessary to pay the principal of, and interest on, bonds issued and sold pursuant 
to this article, as the principal and interest become due and payable. 
(b) The sum necessary to carry out Section 125291.140 appropriated without reqard to fiscal years. 
125291.140. For purposes of carryinq out this article, the Director of Finance may authorize the 
withdrawal from the General Fund of an amount or amounts, not to exceed the amount of the unsold 
bonds thr:it have been authorized by the committee, to be sold for the purpose of carryinq out this r:irtide, 
excludinq any refundinq bonds authorized pursuant to section 125291.155, less any amount loaned 
pursuant to section 125291.145 and not yet repaid, and any amount withdrawn from the General Fund 
pursuant to this section and not yet returned to the General Fund. Any amount withdrawn shall be 
deposited in the Fund. Any money made available under this section shall be returned to the General 
Fund, plus an amount equal to the interest that the money would have earned in the Pooled Money 
Investment Account, from money received from the sr:ile of bonds for the purpose of carryinq out this 
r:irtide. 
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125291.145. The institute may request the Pooled Money Investment Board to make a loan from the 
Pooled Money Investment Account in accordance with Section16312 of the Government Code for the 
purposes of carryinq out this article. The amount of the loan shall not exceed the amount of the unsold 
bonds that the committee, by resolution, has authorized to be sold for the purpose of carryinq out this 
article excludinq any refundinq bonds authorized pursuant to section 125291.155, less any amount 
loaned pursuant to this section and not yet repaid, and any amount withdrawn from the General Fund 
pursuant to Section 125291.140 and not yet returned to the Generr:if Fund. The institute shall execute 
any documents required by the Pooled Money Investment Board to obtain and repay the loan. Any 
amounts loaned shall be deposited in the Fund to be allocated by the institute in accordance with this 
article. 
125291.150. All money deposited in the Fund thm is derived from premium and accrued interest on 
bonds sold shr:ill be reserved in the Fund and shall be available for transfer to the General Fund as a 
credit to expenditures for bond interest, except the amounts derived from premium may be reserved and 
used to pay costs of issuance prior to any transfer to the General Fund. 
125291.155. ThebondsissuedandsoldpursuanttothisarticlemayberefundedinaccordancewithArticle 
6 (commencinq with Section16780) of Chapter 4 of Part 3 of Division 4 of Title 2 of the Government Code, 
which is a part of the State General Obliqation Bond Law. Approvaj by the voters of the state for the 
issuance of the bonds described in this article includes the approval of the issuance of any bonds issued to 
refund any bonds oriqinally issued under this article or any previously issued refundinq bonds. Any bond 
refunded with the proceeds of refundinq bonds as authorized by this section may be leqally defeased to 
the extent permitted by law in the manner and to the extent set forth in the resolution, as amended from 
time to time, authorizinq that refunded bond. 
125291.160. Notwithstandinq any provision of this article or the State General Objiqation Bond Law, if 
the Treasurer sells bonds pursuant to this article that include a bond counsel opinion to the effect that 
the interest on the bonds is excluded from qross income for federal tr:ixpurposes, under desiqnated 
conditions, the Treasurer may maintain separate accounts for the investment of bond proceeds and the 
investment earninqs on those proceeds. The Treasurer may use or direct the use of those proceeds or 
earninqs to pay any rebate, penalty, or other payment required under federal law or to take any other 
action with respect to the investment and use of bond proceeds required or desirable under federal law 
to maintain the tax-exempt status of those bonds and to obtain any other advantaqe under federal law 
on behalf of the funds of this state. 
125291.165. The proceeds from the sale of bonds authorized by this article are not "proceeds of taxes" 
r:isthat term is used in Artide Xlll B of the California Constitution and the disbursement of these proceeds 
is not subiect to the limitations imposed by that article. 
SEC. 25. Section 125292.10 of the Health and Safety Code is hereby amended to read as follows: 
125292.10. Definitions. 
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125292.10. As used in this Chapter and in Article XXXV of the California Constitution, the following terms 
have the following meanings: 
(a) "Act" means the California Stem Cell Research and Cures Act constituting Chapter 3 (commencing 
with Section 125290.10) of Part 5 of Division 106 of the Health and Safety Code. 
(b) "Adult stem cell" means an undifferentiated cell found in a differentiated tissue in an adult organism 
that can renew itself and may, with certain limitations, differentiate to yield all the specialized cell types 
of the tissue from which it originated, such as a cell which is committed to make all of the functional cells 
of the tissue or orqan in which it resides and reqenerates but which is itself undifferentiated. 
(c)"Basic research" means the investiqation of basic mechanisms underlyinq stem cell bioloqy, cellular 
plasticity, cellular differentiation and other vital research opportunities. 
4,e4fgj)"Capitalized interest" means interest funded by bond proceeds. 
M {gl "Committee" means the California Stem Cell Research and Cures Finance Committee created 
pursuant to subdivision (a) of Section 125291.40. 
4,e4"{fl Constitutional officers" means the Governor, Lieutenant Governor, Treasurer, and Controller of 
California. 
(q) "Early development" means discovery of promisinq new stem cell-based technoloqies that could be 
translated to enable broad use and ultimately improve patient care. 
(4 {j3l "Facilities" means buildings, building leases, or capital equipment. 
j,4d {j) "Floating-rate bonds" means bonds which do not bear a fixed rate of interest until their final 
maturity date, including commercial paper notes. 
% {il "Fund" means the California Stem Cell Research and Disease Cures Fund created pursuant to 
Section 125291.25. 
Jp fjl "Grant" means a grant, loan, or guarantee. 
Jffl fil "Grantee" means a recipient of a grant from the institute. All University of California grantee 
institutions shall be considered as separate and individual grantee institutions. 
% "Human reproductive cloning" means the practice of creating or attempting to create a human 
being by transferring the nucleus from a human cell into an egg cell from which the nucleus has been 
removed for the purpose ofimplanting the resulting product in a uterus to initiate a pregnancy. 
Jp fz3l "Indirect costs" mean the recipient's costs in the administration, accounting, general overhead, 
and general support costs for implementing a grant or loan of the institute. NIH definitions ofindirect 
costs will be utilized as one of the bases by the Scientific and Medical Research Standards Working 
Group to create a guideline for recipients on this definition, with modifications to reflect guidance by 
the ICOC and this act. 
J,% {3) "Institute" means the California Institute for Regenerative Medicine. 
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Amended 11.18.19 
W {p) "Interim standards" means temporary standards that perform the same function as "emergency 
regulations" under the Administrative Procedure Act (Government Code, Title 2, Division 3, Part 1, 
Chapter 4-& 3.5, Sections 11340 et seq.) except that in order to provide greater opportunity for public 
comment on the permanent regulations, remain in force for 270 days rather than 180 days. 
W [gJ "Life science commercial entity" means a firm or organization, headquartered in California, whose 
business model includes biomedical or biotechnology product development and commercialization. 
W fzJ"Medical ethicist" means an individual with advanced training in ethics who holds a Ph.D., MA, or 
equivalent training in the bioloqical sciences or the field of clinical medicine or clinical ethics and who 
spends or has spent substantial time (1) researching and writing on ethical issues related to medicine, 
and (2) administering ethical safeguards during the clinical trial process, particularly through service on 
institutional review boards. 
4,e44{51 "Pluripotent cells" means cells that are capable of self-renewal, and have broad potential to 
differentiate into multiple adult cell types. Pluripotent stem cells may be derived from somatic cell 
nuclear transfer or from surplus products of in vitro fertilization treatments when such products are 
donated under appropriate informed consent procedures. These excess cells from in vitro fertilization 
treatments would otherwise be intended to be discarded if not utilized for medical research. 
% {j) "Progenitor cells" means multipotent or precursor cells that are partially differentiated but retain 
the ability to divide and give rise to differentiated cells. 
% {yl "Quorum" means at least 65 percent of the members who are eligible to vote. 
% {yl "Research donor" means a human who donates biological materials for research purposes after 
full disclosure and consent. 
% {ffl "Research funding" includes interdisciplinary scientific and medical funding for 
research, includinq but not limited to ' stem cell discovery research, early development, 
translational research, therapy development, and the development of ' treatments 
through clinical trials, includinq without limitation the reimbursement of patient-qualified costs for 
research participants and their careqivers pursuant to paraqraph (4) of subdivision (b) of Section 
125290.35; the operations of the Workinq Groups, includinq the costs associated with the expert review 
of applications; the costs of advisory qroups and consultants established or retained to evaluate and 
advise the Governinq Board, the Workinq Groups, and awardees; and research conferences. Whena 
facility's grant orloan has not been provided to house all elements of the research, therapy 
development, and/or clinical trials, research funding shall include an allowance for a market lease rate 
of reimbursement for the facility. In all cases, operating costs of the facility, including, but not limited 
to, library and communication services, utilities, maintenance, janitorial, and security, shall be included 
as direct research funding costs. Legal costs of the Institute incurred in order to negotiate standards 
with federal and state governments and research institutions; to implement standards or regulations; to 
resolve disputes; and/or to carry out all other actions necessary to defend and/or advance the Institute's 
mission shall be considered direct research funding costs. 
M [fl "Research participant" means a human enrolled with full disclosure and consent, and participating 
in clinical trials. 
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(y) "Research proqram" means research proiects that are desiqned to advance the same ultimate qoal 
alonq the research continuum and that are conducted by the same or overlappinq investiqators. 
J ffl "Revenue positive" means all state tax revenues generated directly and indirectly by the research 
and facilities of the Institute are greater than the debt service on the state bonds actually paid by the 
General Fund in the same year. 
W {ggl "Stem cells" mean nonspecialized cells that have the capacity to divide in culture and to 
differentiate into more mature cells with specialized functions. 
(ab) "Stem cell discovery research" means basic research, early development, and the discovery, 
evaluation, or improvement of tools and technoloqies in the fields of stem cell and qenetic research and 
other vital research opportunities. 
M 'Vital research opportunity Rtscarch Opportunity" means scientific and medical research and 
technologies, includinq but not limited to qenetics, personalized medicine, and aqinq as a patholoqy, 
and/or any stem cell research not actually funded by the institute under paragraph (3) of subdivision (c) 
of Section 125290.60 which provides a substantially superior research opportunity, vital to advance 
medical science as determined by at least a two-thirds vote of a quorum of the members of the 
Scientific and Medical Research Funding Working Group and recommended as such by that working 
group to the ICOC,or as determined by the vote of a maiority of a quorum of members of the ICOC. 
Human reproductive cloning shall not be a vital research opportunity. 
SEC. 26. Amendment. 
The provisions of this Initiative, except the bond provisions, may not be amended before the measure is 
approved by the voters. The provisions of this Initiative may be amended after its approval by the 
voters by a statute that is passed by a vote of seventy percent of the members of each house of the 
Legislature and signed by the Governor, provided that such amendments are consistent with and further 
the intent of the grant and loan programs created by this Initiative. 
SEC. 27. Severability. 
If any provision of this Initiative, or part of this Initiative, or the application of any provision or part to 
any person or circumstances, is for any reason held to be invalid, the remaining provisions, or 
applications of provisions, shall not be affected, but shall remain in full force and effect, and to this end 
the provisions of this Initiative are severable. If a court were to find in a final, unreviewable judgment 
that the exclusion of one or more entities or activities from the applicability of the Initiative renders the 
Initiative unconstitutional, those exceptions should be severed and the Initiative should be made 
applicable to the entities or activities formerly exempt from the Initiative. It is the intent of the voters 
that this Initiative would have been enacted regardless of whether any invalid provision had been 
included or any invalid application had been made. 
SEC. 28. Conflicting Initiatives. 
(a) In the event that this Initiative and another measure addressing medical research or therapy 
development shall appear on the same statewide ballot, the provisions of the other measure or 
34 
                 
                
                
                 
                
               
  
                 
             
               
             
                  
                
                
   
         
Amended 11.18.19 
measures shall be deemed to conflict with this measure. In the event that this Initiative receives a 
greater number of affirmative votes than a measure deemed to conflict with it, the provisions of this 
Initiative shall prevail in their entirety, and the other measure or measures shall be null and void. 
(b) If this Initiative is approved by the voters but superseded by law by any other conflicting measure 
approved by voters by a greater number of votes at the same election, and the conflicting ballot 
measure is later held invalid, this Initiative shall be self-executing and given full force and effect. 
SEC. 29. Standing. 
Notwithstanding any other provision of law, if the State, or any of its officials fail to defend the 
constitutionality of this Initiative, following its approval by the voters, any other state governmental 
agency of this State shall have the authority to intervene in any court action challenging the 
constitutionality of this Initiative for the purpose of defending its constitutionality, whether such action 
is in state or federal trial court, on appeal, or on discretionary review by the Supreme Court of California 
and/or the Supreme Court of the United States. The reasonable fees and costs of defending the action 
shall be a charge on funds appropriated to the California Department of Justice, which shall be satisfied 
promptly. 
SEC. 30. Liberal Construction. 
This Initiative shall be liberally construed to effectuate its purposes. 
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December 2, 2019 
Hon. Xavier Becerra 
Attorney General 
1300 I Street, 17th Floor 
Sacramento , California 9 5 814 
Attention: Ms. Anabel Renteria 
Initiative Coordinator 
Dear Attorney General Becerra: 
Pursuant to Elections Code Section 9005 , we have reviewed the proposed statutory initiative 
(A.G. File No. 19-0022, Amendment #1) that would authori ze $5.5 billion in general obligation 
bonds for stem cell research and enact various changes to the California Institut e for 
Regenerative Medicine (CIRM). 
Background 
Researchers Use Stem Cells to Study and Treat Various Diseases. Stem cells are certain 
types of cells that exist within humans. Researchers are interested in these types of cells for their 
potential to regenerate lost cells , tissues, and organs. The field of medicine that uses stem cells 
and other techniques for this purpose is known as "regenerative medicine. " One well-known 
example of a regenerative medicin e procedure is a bone marrow transplant. Under this 
procedure , the bone marrow of a donor (which contains stem cells) is transferred to another 
patient to replenish lost blood cells , typically due to certain types of cancer. Scientists are 
researching the use of stem cells to treat many other diseases and health condit ions. 
Voters Established State Stem Cell Research Program . In 2004, voters approved 
Proposition 71, whic h gave researchers in California a constitutional right to conduct stem cell 
research . The measure also created a new state program to fund stem cell research projects , 
research faci lities, and other related activities. In tandem , it created a new entity, CIRM, to 
admini ster the program. The measure also established a CIRM oversight ·structure, which 
includes (1) a 29-member governing board responsible for making funding decisions and 
adopt ing relevant policie s, (2) three working groups responsible for advising the governing 
board, and (3) a five-member committee responsible for providing independent oversight over 
CIRM ' s finances. 
Voters Approved $3 Billion in General Obligation Bonds for Stem Cell Program. To fund 
stem cell grants and CIRM 's operations, the measure authori zed the state to sell general 
obligation bonds. State genera l obligation bonds are a form of borrowing. The state sells the 
bonds to investors , and the proceeds of these sales provide funding to CIRM . The state sells the 
Legislative Analyst's Office 
California Legislature 
Gabriel Petek. Legislative Analyst 
925 L Street. Suite 1000, Sacraml.'.nlo. CA 958 1-1 
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bonds when CIRM needs the funds (typically once a round of grant awardees has been selected). 
Once the bonds are sold to investors, the state begins repaying the investors with interest by 
malcing annual payments over time. Proposition 71 did not specify the length of the repayment 
period for each bond issuance, but the state tended to repay the bonds over ten years. 
Proposition 71 bonds were taxable and a ten-year repayment period is common for these types of 
bonds. (For taxable bonds, the interest that investors earn is not exempt from federal taxes.) 
CIRM Has Spent Nearly All Available Funds. As Figure 1 shows, bonds issued under 
Proposition 71 have comprised virtually all ofCIRM's funding, with a relatively small amount 
of funding coming from investment income, private donations, and other sources. CIRM has 
spent most of the available funding on grants, with smaller amounts spent on CIRM's operations 
and bond costs (discussed later in this letter). As of October 2019, all but $132 million of 
CIRM' s funding has been spent.· According to CIRM staff, the remaining funding will be used 
primarily to oversee active grants. 
Summary of CIRM Budget 
Cumulative Budget Since 2004 (In Millions) 
Funds 
Authorized bonds $3,000 
Investment income 28 
Private donations 9 
Other 6 
Total $3,043 
Uses of Funds 
Grants $2,652" 
CIRM operations 189 
Bond interest payments 68 
Bond issuance costs 3 
Total $2,911 
Remaining Funds $132 
a Includes $269 million In grant funds that have been committed but not 
yet released to grantees. 
CIRM = California Institute for Regenerative Medicine. 
Grants Have Funded Several Different Purposes. As Figure 2 ( on the next page) shows, 
CIRM has awarded about 7 5 percent of grant funds for specific research projects, including 
clinical trials. The remaining 25 percent of grant funds have supported research facility 
construction and equipment, related activities (for example, establishing a network of 
laboratories dedicated to implementing human clinical trials), and various education initiatives 
(for example, research internships for undergraduate students). The University of California has 
received the greatest amount of grant funding, followed by nonprofit universities and institutions 
(such as Stanford University). 
CIRM Is Reducing Staffing Levels. Under Proposition 71, CIRM could spend no more than 
3 percent of bond proceeds on its general administrative costs and no more than 3 percent to 
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administer grants. At full implementation, CIRM reports having over 50 full-time equivalent 
staff. As it nears the end of its programmatic funding, it has reduced operations. Currently, 
CIRM employs 35 full-time equivalent staff. 
Summary of Stem Cell Grants 
$2. 7 Billion in Grant Funding Since 2004 
By Program By Recipient 
!.AO\ 
aRefers to laking a finding from baslo research and converting It Into a treatment hat oan be tested In a cllnlcal lrlal. 
CIRM Used a Small Share of Bond Proceeds for Interest Payments. Typically, the state 
makes regular payments on general obligation bonds from the state General Fund. Proposition 71 
required the state to take a somewhat different approach. For the first five years after receiving 
voter approval, the measure required CIRM to repay interest using the bonds' proceeds. 
According to CIRM, a total of about $70 million of bond proceeds were spent on interest costs 
from 2004 through 2009. In 2010, the state began paying the remaining principal and interest 
from the General Fund. Currently, the state is spending $327 million annually from the General 
Fund to make debt payments on Proposition 71 bonds. 
Small Amount of Funding Spent on Bond Issuance Costs. Typically, certain administrative 
and legal costs are associated with a bond issuance. Proposition 71 specified that bond proceeds 
were to cover these administrative costs. CIRM reports using $2.6 million in bond proceeds for 
these costs. 
Grant Recipients Have Contributed Matching Funds to Their Projects. Many of CIRM's 
programs require a match from grant recipients. The amount of funding that applicants must 
match varies by program. To cover their match, grants recipients can rely on a number of 
different fund sources, including philanthropic donations, federal grants, and industry 
contributions. Many recipients raise more funding than required. According to CIRM, grant 
recipients report collecting a combined $4. 1 billion in matching funds since 2004. 
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Grantees Are Required to Share Invention-Related Income With the State. Some stem cell 
research is expected to lead to new inventions, including new medical technology and 
treatments. Proposition 71 established an expectation that grant recipients share a portion of the 
income resulting from licensing or commercializing these inventions with the state. The state's 
share of the income is deposited into the state General Fund (the state's main operating account), 
which is available to support any state program. Over the years, CIRM's governing board has 
developed specific revenue-sharing policies. Since 2004, grant recipients have contributed 
$352,560 in total invention-related income to the state. 
Proposal 
Authorizes $5.5 Billion in Bonds for Stem Cell Activities. The proposed measure would 
authorize new bonds to fund additional grants and CIRM operations. As Figure 3 ( see next 
page) shows, the measure limits the amount of funds CIRM can spend on its operations. In 
addition, the measure sets aside a portion of bond funds for certain grant programs, such as 
grants for research projects that are aimed at developing treatments and cures for diseases 
affecting the brain and nervous system. For a few of these programs, CIRM's governing board 
would be required to prioritize grant applications that offer matching funds and ensure grant 
awardees are distributed across the state. 
Establishes Certain Rules and Guidelines Relating to the Bonds. The measure would limit 
the amount of bonds the state could sell each year, with the goal of spreading bond sales over at 
least a ten-year period. For the first five years after the measure is enacted, bond proceeds would 
cover any interest payments on the issued bonds. Beginning January 1, 2026, the state would pay 
all remaining debt from the General Fund. The State Treasurer would decide the period over 
which to repay the bonds, with a maximum repayment period of 40 years. 
Makes Numerous Changes to CIRM. The measure would malce various changes to CIRM's 
programs and governance structure. Figure 4 (see page 6) summarizes these changes. One 
notable change would be to refocus some of CIRM' s efforts toward improving patient access to 
stem cell treatments. Under the measure, CIRM would be allowed to hire up to 15 full-time 
equivalent employees to research and develop ways to improve access to treatments. A new 
working group of national experts would advise CIRM's governing board on ways to improve 
access and affordability. Furthermore, the measure would require any revenue earned from 
revenue-sharing agreements to be used to offset patient costs for regenerative medicine 
treatments. 
Fiscal Effects 
Total Estimated State Costs of $7.8 Billion. For the purposes of estimating the cost of the 
measure, we assume the bonds are sold over an initial ten-year period-the minimum period 
required by the measure. We assume each bond is repaid over 15 years, resulting in a total 
repayment period of25 years. Though the typical repayment period for taxable bonds is 
ten years, we assume a somewhat longer period given the measure specifies that the Treasµrer 
could decide to stretch repayments up to 40 years. Under these assumptions, we estimate the 
measure would cost a total of$7.8 billion-$5.5 billion in principal and $2.3 billion in interest. 
The average annual payment over the 25-year period would be $310 million. The costs would be 
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higher or lower than our estimates depending on factors such as the interest rate and the period of 
time over which the bonds are repaid. 
Issuance cost Determined by State Treasurer Legal, underwriter, and other costs to 
Issue the bond. 
Interest payments Determined by bond sales Annual interest payments on any debt 
issued before January 1, 2026. 
-~---=-
General administration Up to 3.5 percent Human resources, finance, 
information technology, and other 
administrative staff at CIRM. 
Grant oversight Up to 3 percent C\RM staff dedicated to oversight of 
grant programs. 
Access to treatments Up to 1 percent CIRM staff focused on improving 
patient access to new stem cell­
der\vecl_tli_era{)les_and treatmrants. 
-Grants 
Community Care Centers of Up to 1.5 percent Start-up costs to establish new sites 
Excellence that conduct human clinical trials. 
Shared Labs Program Up to 0.5 percent Start-up costs to establish state· 
funded facilities devoted to research 
on human embryonic stem cells. 
Research on therapies and $1.5 bllllon Research on Alzheimer's disease, 
treatments for diseases affecting Parkinson's disease, stroke, 
the brain and nervous system dementia, and many other related 
diseases. 
Remaining grants All remaining funds Research programs, clinical trials of 
new treatments, education pipeline 
Initiatives, and other stem 
cell-related programs. 
·=-=~~ ~ [lr~lMl,oi~-=:.-~.--·--·-· --- -
a Amounts/shares are calculated after bond costs have been covered. 
CIRM "" California lnstltule for Regenerative Medicine. 
Likely Low Hundreds of Millions in Interest Payments Paid by Bond Proceeds. Under the 
measure, a portion of the $2.3 billion interest cost would be paid by the bond proceeds. The 
portion of interest repaid from the bond proceeds would depend on the timing of when the state 
begins issuing bonds and the interest rate at which the bonds are sold. Were the state to begin 
issuing bonds shortly after approval of the measure, CIRM would likely make interest payments 
totaling in the low hundreds of millions of dollars from bond proceeds by the end of 2025. 
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Summary of Notable Proposed Programmatic and 
Governance Changes 
Programmatic Changes 
• Would establish grant program to expand sites and facilities supporting 
clinical human trials. 
• Would establish grant program to support stem cell-related 
apprenticeships, graduate fellowships, and other academic programs at 
the California State University and the California Community Colleges. 
• Would require the Callfornla Institute of Regenerative Medicine (CIRM) 
to provide grants for new research facilities at California universities and 
nonprofit institutions. 
• Would require the state to use any Income earned from CIRM agreements 
to Improve the affordability of stem cell treatments. 
Governance Changes 
• Would increase the number of Independent Citizens Oversight Committee 
(ICOC) members from 29 to 35. 
• Would create one new working group to advise ICOC on Improving access 
to regenerative medicine treatments. 
• Would create new advisory boards to advise CIRM on scientific and policy 
matters. 
• Would limit CIRM to 70 lull-time equivalent employees. 
• Would authorize CIRM to hire up to an additional 15 full-time equivalent 
employees, above the 70 employee limit, who would be dedicated to 
improving access to stem cell-derived therapies and treatments. 
Difficult to Estimate Amount of Invention-Related Income Likely to Be Generated. To the 
extent CIRM funds new projects that result in licensed and commercialized products, the state 
would receive a portion of the resulting revenue. The amount of revenue received for this 
purpose is uncertain. Many times, research does not lead to an invention, but, in a few cases, 
inventions do result and are lucrative. Also, a significant amount of time typically elapses from 
an initial research project to commercializing an associated invention. To date, the state has 
collected only a few hundred thousand dollars in invention-related income. Past revenue 
collections, however, might not be a good indicator of future revenue for the reasons cited above. 
Other Possible Fiscal Effects. The measure could result in numerous other indirect effects 
on state and local governments. For example, to the extent the measure results in new treatments 
that are more cost-effective than existing treatments, state and local governments could 
experience savings in some programs such as Medi-Cal, the state's subsidized health care 
program for low-income people. The magnitude of these and other indirect effects is unknown. 
Summary of Fiscal Effects. This measure would have the following major, direct fiscal 
effects: 
• State costs of$7.8 billion to pay off principal ($5.5 billion) and interest ($2.3 billion) 
on the bonds. Associated average annual debt payments of about $310 million for 
25 years. The costs could be higher or lower than these estimates depending on 
factors such as the interest rate and the period oftime over which the bonds are 
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repaid. The state General Fund would pay most of the costs, with a relatively small 
amount of interest repaid by bond proceeds. 
Sincerely, 
c~ 
.h, S"Keely  Martin Bos! 
Director of Finance 
